

Georges Jabboure Netto

University of Alabama at Birmingham
School of Medicine
Faculty Curriculum Vitae

PERSONAL INFORMATION

Name: Georges Jabboure Netto
Citizenship: USA
Foreign Language(s): Arabic, French
Home Address: 1321 Lane Parke Court, Mountain Brook, AL 35223

RANK/TITLE

Professor and Chair
Robert and Ruth Anderson Endowed Chair in Pathology
Department: Pathology
Business Address: 619 19th Street South, Birmingham, AL 35249-7331
Phone: (205) 934-4303
Fax: (205) 934-5499
Email: gnetto@uabmc.edu

HOSPITAL AND OTHER (NON ACADEMIC) APPOINTMENTS

2016 – Present Pathologist-in-Chief, University of Alabama Hospital; Birmingham, AL
2016 – Present Medical Staff, University of Alabama Health System, Birmingham, AL
2012 – 2013 Johns Hopkins International Medical Director of Clinica Las Condes, Santiago, Chile.
2011 – 2012 Medical Director of Amcare Labs International Inc. An Affiliate of Johns Hopkins International
2011-2016 Director of Surgical Pathology Molecular Diagnostics, Johns Hopkins Hospital

EDUCATION

1979 - 1985 M.D. Damascus University, Damascus, Syria

LICENSURE

1991	Texas	H8282		
2004	New York	234249		
2005	District of Colombia	MD035373	2005	Maryland 911785
2016	Alabama	L4425DP		

BOARD CERTIFICATION

1992 American Boards of Anatomic and Clinical Pathology
2005 American Boards of Molecular Genetic Pathology

POSTDOCTORAL TRAINING

1987 – 1991 Residency in Anatomic & Clinical Pathology, Baylor University Medical Center, Dallas, TX
1991 – 1992 Chief Resident, Department of Pathology, Baylor University Medical Center Dallas, TX
1992 – 1993 Surgical Pathology Fellowship, Lauren V. Ackerman Laboratory, Barnes Hospital, Washington University School of Medicine, St. Louis, MO
1993 – 1994 Urologic Pathology Fellowship, Memorial Sloan-Kettering Cancer Center, New York, NY

ACADEMIC APPOINTMENTS

2016 – Present Chair, Department of Pathology, Schools of Medicine and Dentistry, University of Alabama at Birmingham, Birmingham, AL
2016 – Present Scientist, Comprehensive Cancer Center

2016 – 2017 Adjunct Professor of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

2013 – 2016 Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD

2013 – 2016 Professor of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD

2013 – 2016 Professor of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD

2012 – Present Scientific Advisory Board Member, Cambridge Health Institute (CHI)

2010 – 2011 Chair, Solid Tumor Division, Association of Molecular Pathology (AMP)

2009 – 2013 Johns Hopkins International Medical Director of Clinica Las Condes Comprehensive Cancer Center, Santiago, Chile.

2008 – 2013 Associate Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD

2007 – 2013 Associate Professor of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD

2007 – 2011 Chair, Immunology Devices Panel, Medical Devices Advisory Committee, FDA

2005 – 2016 Staff Pathologist, Johns Hopkins Hospital

2005 – 2016 Staff Pathologist, Johns Hopkins Bayview Medical Center

2005 – 2016 Staff Pathologist, Howard County General Medical Center

2005 – 2013 Associate Professor of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD

2004 – 2005 Chief of Pathology and Laboratory Medicine, Washington, D.C. Veterans Affairs Medical Center, Washington, D.C.

2004 – 2005 Associate Professor of Pathology, The George Washington University School of Medicine, Washington, D.C.

2001 – 2004 Director of Molecular Pathology, Baylor University Medical Center, Dallas, TX

1999 – 2004 Director of Tissue Bank & Tissue Procurement, Baylor University Medical Center, Dallas, TX

1998 – 2002 Director of Residency Training Program, Department of Pathology, Baylor University Medical Center, Dallas, TX

1996 – 2004 Associate Attending in Pathology (provisional status 96-98), Baylor University Medical Center, Dallas, TX

1995 – 1996 Assistant Professor in Clinical Pathology, State University of New York at Stony Brook, Stony Brook, NY

1994 – 1996 Chief of Anatomic Pathology, Northport Veterans Affairs Medical Center, Northport, NY

AWARDS/HONORS

2007 The Johns Hopkins Hospital Department of Pathology Housestaff's Faculty Teaching Award for Anatomic Pathology

2010 The Johns Hopkins Hospital Department of Urology Housestaff's Faculty Teaching Award

PROFESSIONAL SOCIETIES

1993 – 2014 College of American Pathology

1993 – 2014 American Society of Clinical Pathology

1994 – Present US and Canadian Academy of Pathology

1996 – Present International Academy of Pathology - Arab Division

1998 – Present Association of Molecular Pathology

2004 – 2005 American College of Medical Genetics

2005 – Present International Society of Urologic Pathology

2006 – Present American Urologic Association

MEMBERSHIPS

2007 – 2010	Member, Scientific Abstract Review Board, US and Canadian Academy of Pathology (USCAP)
2009	Moderator, Genitourologic Pathology Proferred Paper Session, US and Canadian Academy of Pathology (USCAP) Meeting, Boston
2009 – 2010	Member, Annual Meeting Program Committee, Association of Molecular Pathology (AMP) 2010 Annual Meeting, San Jose, CA
2010	Moderator, Solid Tumor Plenary Session, Association of Molecular Pathology (AMP) 2010 Annual Meeting, San Jose, CA
2010	Moderator, Solid Tumor Symposium, Association of Molecular
2010 – 2011	Member, Annual Meeting Program Committee, Association of Molecular Pathology (AMP) 2011 Annual Meeting, San Jose, CA
2011	Co-Moderator: Association of Molecular Pathology (AMP) and American Society of Clinical Pathology (ASCP) Combined Companion Meeting at The United States and Canadian Academy of Pathology 2011 Annual Meetings; <i>Gene Patents: The Future of Gene Research in an Era of Patents- Scientific and Legal Considerations</i> , San Antonio, TX
2011	Co-Moderator: Solid Tumor Workshop, <i>microRNA Applications in Oncology</i> Association of Molecular Pathology (AMP) 2011 Annual Meeting, Dallas, TX
2011	Co-Moderator: Platform Presentations of Selected Solid Tumors Abstracts Association of Molecular Pathology (AMP) 2011 Annual Meeting, Dallas, TX
2011	Moderator: Solid Tumor Workshop, <i>Lung and Colorectal Cancer Guidelines</i> Association of Molecular Pathology (AMP) 2011 Annual Meeting, Dallas, TX
2011	Co-Moderator: Plenary Session, <i>Next Generation Sequencing</i> Association of Molecular Pathology (AMP) 2011 Annual Meeting, Dallas, TX
2012	Co-Moderator: American Society for Investigative Pathology (ASIP) in Coordination with Association for Molecular Pathology (AMP) Joint Session with American Society for Clinical Pathology (ASCP). A companion meeting of The United States and Canadian Academy of Pathology 2012 Annual Meetings; <i>Genomic Pathology in Clinical Diagnostics: Promises and Pitfalls of New Technologies</i> , Vancouver, Canada
2012 – 2015	The College of American Pathology (CAP): Prostate Advanced Practical Pathology Program (AP3): a member of expert faculty group tasked with building a comprehensive cognitive and practical assessment certificate program comprising web based and in person educational modules and lecture; administered twice annually starting April 2014
10/2014	Co-Chair; Bladder Symposium: Bladder pathology update for the practicing pathologist 30th International Congress of the International Academy of Pathology (IAP2014) Bangkok, Thailand
03/2015	US and Canadian Academy of Pathology (USCAP) Special Course Co-Director: "Molecular Diagnostic and Genomic Applications in Cancer: A Primer for The Pathologist" Boston, USA
03/2016	US and Canadian Academy of Pathology (USCAP) Special Course Co-Director: "Molecular Diagnostic and Genomic Applications in Cancer: A Primer for The Pathologist" Boston, USA
03/2017	US and Canadian Academy of Pathology (USCAP) Special Course Co-Director: "Molecular Diagnostic and Genomic Applications in Cancer: A Primer for The Pathologist" Boston, USA
03/2018	US and Canadian Academy of Pathology (USCAP) Special Course Co-Director: "Molecular Diagnostic and Genomic Applications in Cancer: A Primer for The Pathologist" Boston, USA
10/2014 – 10/2016	Nominating Committee member, Association of Molecular Pathology (AMP)

10/2016 – Present Professional Relation Committee member, Association of Molecular Pathology (AMP)

COUNCILS AND COMMITTEES

Advisory and Professional Society Committees

2005 – 2007 Member, Immunology Devices Panel, Medical Devices Advisory Committee & Center for Devices and Radiological Health, Food and Drug Administration (FDA)

2007 – 2011 Chair, Immunology Devices Panel, Medical Devices Advisory Committee & Center for Devices and Radiological Health, Food and Drug Administration (FDA)

2009 – 2010 Chair-Elect, Solid Tumor Division, Association of Molecular Pathology

2009 – Present Grant Application Reviewer, Cancer Research UK, London, England

2009 – Present Grant Application Reviewer, Agency for Science, Technology and Research's (A*STAR) Biomedical Research Council; Singapore

2010 – Present Association of Molecular Pathology Council Member

2011 – 2016 Consultant, Immunology Devices Panel, Medical Devices Advisory Committee & Center for Devices and Radiological Health, Food and Drug Administration (FDA)

2012 – Present Scientific Advisory Board Member, Cambridge Health Institute (CHI)

2012 – 2016 Patrick C Walsh Prostate Cancer Research Fund Grants Review Committee

2014 – Present Genentech National Pathology Advisory Board

2015 International Advisory Board Member: Canadian Journal of Pathology, official publication of the Canadian Association of Pathologists

2015 IARC-World Health Organization: Member of the Urinary Bladder Consensus and Editorial Group of the "WHO Classification of Tumours of the Urinary System and Male Genital Organs"

2016 – Present University of Alabama Health Services Foundation, P.C. Executive Committee

2016 – Present Clinical Chairs Council

2016 – Present School of Medicine Executive Council

2016 – Present UAB Health System Medical Executive Committee

UNIVERSITY ACTIVITIES

Research Program Building/Leadership

1998 – 2004 Member, Institutional Review Board (IRB), Baylor University Medical Center

1998 – 2004 Member, Research Committee, Baylor Hepatobiliary Institute

2006 – Present Member Committee on Information Systems to Support Clinical Investigation, Johns Hopkins University

2006 – Present Task Force Committee on Biospecimen Tracking and Storage, Johns Hopkins University

EDUCATIONAL PROGRAM BUILDING/LEADERSHIP

1998 – 2002 Director of Residency Training Program, Department of Pathology, Baylor University Medical Center, Dallas, TX

1999 – 2002 Member, Graduate Medical Education Committee, Baylor University Medical Center

2004 – 2005 Member, Pathology Residency Training Committee, George Washington University School of Medicine

2005 – Present Member, Pathology Residency Training Committee, Johns Hopkins University

INSTITUTIONAL ADMINISTRATIVE APPOINTMENT

1998 – 2004 Member, Institutional Review Board (IRB), Baylor University Medical Center

1998 – 2004 Member, Research Committee, Baylor Hepatobiliary Institute

2002 – 2004 Member, Surgical Pathology Quality Improvement Committee, Baylor University Medical Center

1999 – 2002	Member, Graduate Medical Education Committee, Baylor University Medical Center
2001 – 2004	Member, Credentialing Committee, Southwest Physician Alliance
2004 – 2005	Member, Pathology Residency Training Committee, George Washington University School of Medicine
2004 – 2005	Member, Chief of Staff Committee, Washington, D.C. Veterans Affairs Medical Center
2004 – 2005	Member, Medical Center Director Committee, Washington, D.C. Veterans Affairs Medical Center
2005 – 2015	Member, Pathology Residency Training Committee, Johns Hopkins University
2006 – 2016	Member Committee on Information Systems to Support Clinical Investigation, Johns Hopkins University
2006 – 2016	Task Force Committee on Biospecimen Tracking and Storage, Johns Hopkins University
2007 – 2010	Chair, Anatomic Pathology/Molecular Diagnostic Pathology Steering Committee, Johns Hopkins University

EDITORIAL BOARD MEMBERSHIPS

1998 – 2004	Baylor University Medical Center Proceedings
2009 – Present	Pathology
2010 – Present	Associate Editor: Translational and Basic Research Section. “Urology” (The Gold Journal),
2010 – Present	Human Pathology
2011 – Present	International Journal of Surgical Pathology
2013 – Present	The Prostate
2013 – Present	Associate Editor, Urology Case Report
2013 – Present	Associate Editor, Virchows, European Journal of Pathology
2016 - Present	Associate Editor, Advances in Anatomic & Molecular Pathology
2017	Guest Editor of Virchows, European Journal of Pathology Annual Review Issue titled “Molecular pathology in the era of precision medicine”

ONLINE JOURNALS

2008 – 2011	Association of Molecular Pathology Web Editorial Board; Solid Tumor Editor
2009 – 2018	Pathology and Laboratory Medicine International
2010 – 2013	Journal of Molecular Biomarkers and Diagnosis
2010 – Present	The International Journal of Clinical and Experimental Pathology
2011 – Present	The Scientific World Journal
2012 – Present	The World journal of Clinical Urology

AD HOC REVIEWER

2005 – Present	Cancer
2006 – Present	Journal of Urology
2006 – Present	Modern Pathology
2006 – Present	Laboratory Investigation
2006 – Present	Liver International
2007 – Present	Experimental and Molecular Pathology
2007 – Present	Histology and histopathology
2007 – Present	Archives of Pathology & Lab Medicine
2008 – Present	Journal of Carcinogenesis
2008 – Present	International Journal of Cancer
2009 – Present	World Journal of Surgical Oncology

2009 – Present	Cancer Biomarkers
2009 – Present	Neoplasia
2009 – Present	European Journal of Obstetrics & Gynecology and Reproductive Biology
2009 – Present	Histopathology
2009 – 2013	International Journal of Surgical Pathology
2009 – 2013	Prostate
2010 – Present	Clinical Cancer Research
2010 – Present	International British Journal of Urology
2012 – Present	Cancer Epidemiology, Biomarkers & Prevention
2013 – Present	Journal of Investigative Medicine
2013 – Present	Virchows Archives of Pathology
2015 – Present	Lancet
2017 – Present	Nature Reviews, Urology

MAJOR RESEARCH INTERESTS (2-3 Sentences)

Primary research interest and contributions have focused on the evaluation of molecular biomarkers that can serve as potential markers of early detection, prognostication and therapeutic targets in the management of urologic malignancies.

TEACHING EXPERIENCE

1995 – 1996	First Year Medical Student Pathology Lab Sessions State University of New York at Stony Brook, Stony Brook, NY
1999 – 2002	Director of Residency Training Program, Department of Pathology Baylor University Medical Center, Dallas, TX
1999 – 2002	Graduate Medical Education Committee, Baylor University Medical Center, Dallas, TX
2004 – 2005	Pathology Residency Training Committee, George Washington University School of Medicine, Washington, D.C.
2004 – 2005	Second Year Medical Student Pathology Course, small group instructor, George Washington University School of Medicine, Washington, D.C.
2005 – 2016	Surgical Pathology Resident's Teaching Conference, Johns Hopkins University, Baltimore, MD
2007 – 2016	Second Year Medical Student Pathology Course, small group instructor, Johns Hopkins University, Baltimore, MD
2008 – 2016	Second Year Medical Student Pathology Course, Lectures, Johns Hopkins University, Baltimore, MD
2005 – 2016	Urology Residents Teaching Conference, Johns Hopkins University, Baltimore, MD

CLINICAL INSTRUCTION

1998 – 2004	Anatomic and Clinical Pathology Residents, Baylor University Medical Centre
2004 – 2005	Anatomic and Clinical Pathology Residents. George Washington University, Washington, D.C.
2005 – 2016	Anatomic Pathology Residents. Johns Hopkins University
2005 – 2016	Urologic Pathology Post Doctoral Clinical and Research Fellows, Johns Hopkins University

WEB-BASED CME CONFERENCES

07/30/2007	Surgical Pathology Unknown Conference – Week 319 http://pathology.jhu.edu/departments/teaching.cfm
10/01/2007	Pathology Unknown Conference – Week 326 http://pathology.jhu.edu/departments/teaching.cfm

11/12/2007 Surgical Pathology Unknown Conference – Week 331
<http://pathology.jhu.edu/department/teaching.cfm>

02/18/2008 Surgical Pathology Unknown Conference – Week 304
<http://pathology.jhu.edu/department/teaching.cfm>

03/17/2008 Surgical Pathology Unknown Conference – Week 343
<http://pathology.jhu.edu/department/teaching.cfm>

08/18/2008 Surgical Pathology Unknown Conference – Week 355
<http://pathology.jhu.edu/department/teaching.cfm>

08/18/2008 Surgical Pathology Unknown Conference – Week 362
<http://pathology.jhu.edu/department/teaching.cfm>

09/29/2008 Surgical Pathology Unknown Conference – Week 367
<http://pathology.jhu.edu/department/teaching.cfm>

10/20/2008 Surgical Pathology Unknown Conference – Week 369
<http://pathology.jhu.edu/department/teaching.cfm>

03/23/09 Surgical Pathology Unknown Conference – Week 386
<http://pathology.jhu.edu/department/teaching.cfm>

05/11/09 Surgical Pathology Unknown Conference – Week 392
<http://pathology.jhu.edu/department/teaching.cfm>

07/06/09 Surgical Pathology Unknown Conference – Week 398
<http://pathology.jhu.edu/department/teaching.cfm>

11/09/09 Surgical Pathology Unknown Conference – Week 415
<http://pathology.jhu.edu/department/teaching.cfm>

12/09 American Society of Clinical Oncology ASCO University
 Colorectal Cancer: **ASCO Tumor Boards**
<http://university.asco.org/colorectal-cancer-tumor-board>

01/25/10 Surgical Pathology Unknown Conference – Week 422
<http://pathology.jhu.edu/department/teaching.cfm>

03/01/10 Surgical Pathology Unknown Conference – Week 426
<http://pathology.jhu.edu/department/teaching.cfm>

07/04/10 Surgical Pathology Unknown Conference – Week 441
<http://pathology.jhu.edu/department/teaching.cfm>

08/23/10 Surgical Pathology Unknown Conference – Week 448
<http://pathology.jhu.edu/department/teaching.cfm>

10/18/10 Surgical Pathology Unknown Conference – Week 455
<http://pathology.jhu.edu/department/teaching.cfm>

02/2011 American Society of Clinical Oncology ASCO University
 Prostate Cancer: **ASCO Tumor Boards**
<http://university.asco.org/prostate-cancer-asco-tumor-boards>

04/2011 Surgical Pathology Unknown Conference – Week 475
<http://pathology.jhu.edu/department/teaching.cfm>

04/18/2011 Surgical Pathology Unknown Conference – Week 476
<http://pathology.jhu.edu/department/teaching.cfm>

07/04/2011 Surgical Pathology Unknown Conference – Week 487
<http://pathology.jhu.edu/department/teaching.cfm>

07/11/2011 Surgical Pathology Unknown Conference – Week 488
<http://pathology.jhu.edu/department/teaching.cfm>

07/18/2011 Surgical Pathology Unknown Conference – Week 489
<http://pathology.jhu.edu/department/teaching.cfm>

10/10/2011 Surgical Pathology Unknown Conference – Week 499
<http://pathology.jhu.edu/department/teaching.cfm>

10/17/2011 Surgical Pathology Unknown Conference – Week 500
<http://pathology.jhu.edu/department/teaching.cfm>

05/14/2012 Surgical Pathology Unknown Conference – Week 511
<http://pathology.jhu.edu/department/teaching.cfm>

02/25/2013 Surgical Pathology Unknown Conference – Week 548
<http://pathology.jhu.edu/department/teaching.cfm>

04/2014 Prostate Advanced Practical Pathology Program (AP3)
The College of American Pathology (CAP)
 “Introduction”

04/2014 Prostate Advanced Practical Pathology Program (AP3)
The College of American Pathology (CAP)
 “Challenging Tumors”

06/2014 Practice UPDATE Clinical Implications of Mixed-Grade Bladder Tumors
<http://www.practiceupdate.com/journalscan/9942>

POST DOCTORAL FELLOWS

08/01/2006 – 06/30/2007 Sana Jadallah, MD
 Attending Pathologist
 New York –Presbyterian Hospital Queens, NY NY

10/09/2006 – 06/30/2008 Antoun Toubaji, MD
 Assistant Professor Department of Pathology
 George Washington School of Medicine Washington, D.C., USA

11/01/2007 – 12/30/2008 Roula Albadine, MD
 Associate professor
 CHUM Montréal (Montreal University) Montreal, Canada

02/09/2009 – 03/31/2010 Luciana Schultz, MD
 PhD Candidate at AC Camargo, São Paulo, Pathology Department,
 under Dr. Fernando A. Soares MD, Pathologist in Practice and
 Technical Director at Insitituto de Anatomia Patológica, Piracicaba,
 São Paulo.

08/02/2010 – 12/31/2011 Alcides Chaux, MD
 Professor of Pathology
 Universidad del Norte School of Medicine, Asuncion, Paraguay,

07/01/2011 – 06/30/2012 Nilda Gonzalez Roibon. MD
 Surgical Pathology Fellow
 Hospital Universitario Austral (HUA) Buenos Aires, Argentina

07/01/2012 – 06/30/2013 Enrico Munari MD
 PGY4th Resident in Anatomical Pathology Department of Pathology
 and Diagnostics University of Verona, Verona, Italy

08/01/2012 – 07/31/2013 Sheila F. Faraj MD
 Faculty
 Department of Pathology and Centro de Investigaçao Translacional
 em Oncologia Instituto do Câncer do Estado de São Paulo (Sao
 Paulo State Cancer Institute) University of São Paulo, São Paulo,
 Brazil

07/01/2013 – 06/30/2014 Stephania Martins Bezzera MD
 Faculty Pathologist
 Department of Anatomic Pathology
 A.C. Camargo Cancer Center São Paulo, Brazil

04/01/2014 – 03/30/2015 Gunes Guner MD
 Post-Doctoral GU research Fellow Johns Hopkins University

06/01/2014 – 05/15/2015 Leonardo Oliveira Reis MD, MSc, PhD
 Professor of Urology and Urologic Oncology

07/01/2014 – 06/30/2015	Pontifical Catholic University of Campinas - PUC-Campinas, Campinas, São Paulo, Brazil Maria Angelica Mendoza MD Attending Pathologist Laboratory of Pathology Clinica las Americas Medellín Antioquia COLOMBIA
01/01/15 – 01/01/2016	Diane Taheri, MD, Professor of Pathology Tehran University, Iran

PHD THESIS REVIEW

02/15/18 Enrico Munari, Final Exam External Reviewer, University of Verona, Italy

MAJOR LECTURES AND VISITING PROFESSORSHIPS

04/2011	<u>Planary Speaker:</u> The Oncologist meet the Pathologist Conference. Hot Topics in Genito-Urinary Oncology. Corso Residenziale: L'oncologo incontra il patologo: le neoplasie dell'apparato genito-urinario. II edizione, Arezzo, Italy
04/2012	<u>Visiting Professor University of Toronto:</u> Annual Postgraduate Trainee Research Day, Department of Laboratory Medicine and Pathobiology. <i>Personalized Medicine: A New Landscape for Laboratory Medicine Practice</i> , Toronto, Canada
05/2012	<u>Visiting Professor University of Calgary:</u> Annual Residents Research Day 2012 The Paul Kneafsey Lecture- <i>Molecular Advances in Urologic Malignancies: Are We There Yet?</i> Department of Pathology and Laboratory Medicine. Calgary, Canada
09/2012	<u>Keynote Speaker</u> International Academy of Pathology (IAP), the Indian Division 15 th CME 2012 at The Armed Forces Medical College. "Pathology in the Era of Personalized Cancer Management". Pune, India
04/2013	<u>Pathology Visiting Professor & Grand Round Speaker, Department of Pathology, Beth Israel Deaconess Hospital:</u> Molecular Advances in Bladder Cancer: Implications for Prognostics and Therapeutics Harvard University, Boston, MA
10/2013	<u>The Zaklada Sergei Saltykov Lecture:</u> Oncologic Surgical Pathology in the Era of Precision Medicine University of Zagreb, Zagreb, Croatia
01/2014	<u>Pathology Visiting Professor & Grand Round Speaker: Department of Pathology, Brigham and Women Hospital:</u> the Molecular Pathology of Prostate Cancer Harvard University, Boston, MA
02/2014	<u>The Vladimir Totovic Lecture, The International Academy of Pathology (IAP), German Division:</u> Oncologic Pathology in the Era of Precision Medicine: The Impact of Genomics Bonn, Germany
06/2015	<u>Keynote lecture The Canadian Association of Pathologists 2015 Annual Meeting PRONTO workshop:</u> The Biopsy Diagnosis of Prostate Cancer: Variant Histology, Benign Mimickers and Small High Grade Foci.
04/2016	<u>Djordje Joannovic Key Note Lecture at the Serbian Society of Pathology:</u> Genomic Applications in Solid Tumors: The Metamorphosis of the Surgical Pathologist, Zlatibor, Serbia.
04/2017	<u>Grand Round in Anatomic Pathology, MD Anderson Cancer Center:</u> "Prostate Cancer Risk Categorization: Integration of Morphology and Genomics." The University of Texas, Texas.
06/2017	<u>Visiting Professor & Grand Rounds in Pathology, University of Zagreb:</u> Prostate Cancer Management: Integration of Morphology and Genomics. Zagreb, Croatia
03/12/18	<u>Visiting Professor & LMP Monday Seminar Series, University of Toronto,</u> "Changing Landscape of Bladder Cancer Management: The Impact of Genetics and Immunotherapy", Toronto, Canada

EXTRAMURAL FUNDING

(Banchereau) CapCure Role: Co-investigator Induction of Prostate Cancer Specific CD8 T Cells with Cell Body Loaded DC IV ONYX-015 (Nemunaitis) ONYX Inc Role: Co-Investigator Ph I Ad-mda7 (INGN 241) (Nemunaitis) Introgen Therapeutics Inc. Role: Co-Investigator R01 CA89440-01A1 (Banchereau) NIH/NCI Role: Co-Investigator Dendritic Cells and Breast Cancer Immunity (Pippen) Avantis Role: Co-Investigator The Role of HER2/neu Amplification by FISH in Predicting Response to Adjuvant Chemotherapy in Breast Carcinoma Hepatitis C 3 Trial (Klintmalm) Roche Pharmaceutical Grant Role: Co-investigator and National Central Pathologist Reviewer R21AR056373 (Kominsky) NIH/NCI Role: Co-Investigator Effect of MIP-1 delta on Osteoclast Development and Pathological Bone Resorption (Platz) Patrick C Walsh Prostate Cancer Foundation Role: Co-Investigator Does interleukin-10 predict prostate cancer incidence and recurrence? (Lupold) Patrick C Walsh Prostate Cancer Foundation Role: Co-Investigator The Oncogenic miR-21 Gene Locus in Advanced Prostate Cancer (Trink) Flight Attendant Medical Research Institute (FAMRI) Role: Co-Investigator Role of GPI Complex Subunits in Human Bladder Cancer (Hoque) NIH/NCI R03CA128060 Role: Co-Investigator Identification of Biomarkers for Testicular Cancer (Casero) Patrick C Walsh Prostate Cancer Research Fund Role: Co-Investigator SMO/PAOh1 Expression in Prostatic Carcinoma (Demarzo) NIH/NCI Role: Co-Investigator Inter-SPORE Prostate Biomarkers Study Centralized Pathology Core IPBS-CPS PO1CA077664 (Sidransky)	01/01/2000 – 12/31/2000 \$100,000 2001 – 2002 2001 – 2004 08/01/01 – 07/31/05 \$383,749 2002 – 2003 \$50,000 08/15/02 – 08/15/05 \$2,183,641 07/01/09 – 06/30/11 \$125,000 04/01/09 – 03/30/11 \$75,000 04/01/09 – 03/30/11 \$75,000 07/01/2007 – 2010 \$100,000 09/24/2007 – 09/23/09 \$50,000 04/01/06 – 03/31/2008 \$75,000 04/01/06 – 03/31/2008 \$193,327 05/31/2005 – 11/30/2009	1.2 calendar 3 calendar 0.6 calendar 0.6 calendar 0.24 calendar 0.24 calendar 0.12 calendar 0.48 calendar 0.72 calendar 3.0 Calendar
--	--	---

NIH/NCI	\$50,786	
Role: Co-Investigator		
High Throughput Genetic Analysis of Bladder Cancer: Tissue Core A (Netto)	04/01/2007 – 03/31/2008	0.48 calendar
Patrick C Walsh Prostate Cancer Research Fund	\$75,000	
Evaluation of TMPRSS2/ETS fusion genes by FISH in Progression Prostate Carcinoma TMA (Netto)	02/01/06 – 10/31/2007	
Prostate Cancer Foundation	\$75,000	0.48 Calendar
Biomarker Expression in Prostate Cancer TMAs 1RC2CA148086-01(Trock)	09/29/2009 – 08/31/12	0.24 calendar
NIH		
Role: Co-Investigator		
Biomarker Prediction of Gleason Upgrading 90038088 (Netto)	\$645,082 07/01/09 – 06/30/12	1.2 calendar
Flight Attendant Medical Research Institute	\$108,000 (FAMRI)	
Methylation Markers of Bladder Cancer Recurrence P50DK082998 (Getzenberg)	09/30/09 – 06/30/13	0.48 calendar
NIDDK	\$631,739	
Role: Co-Investigator		
Novel Translational Approaches to BPH/LUTS		
The goal of this O'Brien Center application is to evaluate biomarker and epidemiologic tools to BPH/LUTS. (Cho)		
Prostate Cancer Foundation	09/01/11 – 06/31/14	0.36 calendar
Creativity Award	\$150,000	
Role: Co-Investigator		
F-DCFBC PET radiotracer primary prostate cancer pilot study. The major goals of this project are to conduct initial preliminary 18F-DCFBC PSMA small molecular PET imaging of primary prostate cancer as an imaging biomarker of prostate cancer aggressiveness and progression.		
W81XWH-10-2-0056 (Trock)	06/07/10 – 05/31/14	1.20 calendar
DOD	\$1,298,965	
Role: Co-PI		

Prostate Cancer Research Program Pathology Resource Network Johns Hopkins Prostate Cancer Pathology Resource Network (coordinating Centre)

This project will coordinate among 3 institutions the development of a prostate cancer biorepository with well-annotated specimens obtained using optimized and standardized protocols, and to conduct biospecimen science to characterize critical factors influencing the molecular integrity of research tissues. Johns Hopkins has 2 roles in this Network: it serves as the Coordinating Center to coordinate activities among all 3 sites, and it serves as one of the Network Sites responsible for collecting tissue specimens and conducting biospecimen science research. The specific aims for these 2 roles will be listed separately.

R01CA143299 (Lupold)	07/01/10 – 04/30/15	0.24 calendar
NCI	\$201,275	
MicroRNA's in Advanced Prostate Cancer: A MiR-21 Model		
The objective of this study is to evaluate the contribution of miR-21 to prostate cancer progression and to identify the biologic pathways in which miR-21 participates.		
P50 CA58236 (Nelson)	09/01/08-08/31/15	0.24 calendar
NIH-NCI	\$134,001	
SPORE in Prostate Cancer		
Core B – Specimen Core (De Marzo/Netto)		

The major goals of this project are to perform a prospective study of tissue and serum biomarkers for prediction of aggressiveness of prostate cancer. The study is also a pilot for the National Biospecimen Network

W81XWH-12-1-0605 (Luo)	09/30/12 – 09/29/15	.036 calendar
DOD	\$122,889	

Role: Co-Investigator

Molecular Indicators of Castration-Resistant Prostate Cancer

The goal of this project is to develop a molecular detection assay that can be used to evaluate the overall castration resistant phenotype for prediction and monitoring of hormone therapy resistance.

W81XWH-11-PCR-IDA (Kulkarni)	09/30/12 – 09/29/15	0.6 calendar
Department of Defense (DOD) PC111398	\$123,184	

Role: Co-Investigator

Multiplex Cancer/Testis Antigen-Based Biomarker Panel to Predict the Aggressive Phenotype of Prostate Cancer (Hurley)

Department of Defense (DOD)	09/01/12 – 08/31/15	0.3 calendar
	\$364,500	

Role: Co-Investigator

ASPN, A Novel Inhibitor of TGFbeta and a Putative Biomarker for Aggressive Prostate Cancer (Sidransky)

1R01CA163594-01	04/01/12 – 03/31/17	0.60 calendar
NIH/NCI	\$250,000	

Role: Co-Investigator

Discovery and Characterization of Methylation Markers for Molecular Detection and Prevention

The overall goal of this project is to identify methylation markers for early detection and targeted therapy. (Netto)

JHGBCI	10/1/15 – 09/30/16	
	\$50,000	

TERT-Promoter Mutations Urine Assay for Early Detection and Monitoring of Bladder Cancer. The main aim of the study are to determine the specificity and sensitivity of a novel TERT promoter mutations assay in detecting bladder cancer in urine samples of individuals at high risk for the disease and its utility during surveillance to monitor disease recurrence.

PEER-REVIEWED ORIGINAL RESEARCH ARTICLES

1. **Netto GJ**, Cheek JH, Zachariah NY, Romer JC, Lee CF, Schoenfeld R, Chakmakjian ZH. Steroid receptors in benign mastectomy tissue. *Am J Clin Pathol* 1990; 94:14-7.
2. Urshel HC, Razzuk MA, **Netto GJ**, Disiere J, Chung SY. Sclerosing mediastinitis: improved management with histoplasmosis titer and ketoconazole. *Ann Thorac Surg* 1990; 50:215-21.
3. Hagans JE, Harms SE, Pierce WB, Cheek JH, Flamig DP, Griffey RH, Savino DA, **Netto GJ**, et al. MRI and breast cancer: a new magnetic resonance technique specifically designed for the breast. *Proc (Bayl Univ Med Cent)* 1991; 16(4):17-20.
4. Solomon H, Gonwa T, Mor E, Holman M, Gibbs J, Watemberg I, **Netto GJ**, Goldstein R, Husberg B, Klintmalm G. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. *Transplantation* 1993; 55(1):87-91.
5. Tong AW, Huang Y, Zhang B, **Netto GJ**, Vitetta E, Stone MJ. Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. *Anticancer Res* 1993; 13(3):593-8.
6. Harms SE, Flamig DP, Hesley KL, Evans WP, Cheek JH, Peters GN, Knox SM, Savino DA, **Netto GJ**, Wells R, Jones SE. Fat-suppressed three-dimensional MR imaging of the breast. *Radiographics* 1993; 13(2):247-267.

7. Sarkis A, Bajorin D, Reuter V, Herr H, **Netto GJ**, Zhang Z-F, Schultz P, Cordon-Cardo C, Scher H. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. *J Clin Oncol* 1995; 13(6):1384-90.
8. Mor E, Tillery W, Solomon H, **Netto GJ**, Watenberg I, Klintmalm G. The predictive value of hepatocyte glycogen content on liver allograft biopsy. Correlation with early graft function. *Transplantation* 1995; 59(1):141-3.
9. Scher H, Sarkis A, Reuter V, Cohen D, **Netto GJ**, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. *Clin Cancer Res* 1995;1(5):545-50.
10. Nord JD, Stolfi RL, Alfieri AA, **Netto GJ**, Reuter V, Sternberg SS, Colofiore JR, Koultscher JA, Martin DS. Apoptosis induced in advanced CD8F1- murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion. *Cancer Chemother Pharmacol* 1997; 40(5):376-84.
11. Fabia R, Levy M, Crippin J, Tillery W, **Netto GJ**, Aguanno J, Dysert P, Goldstein R, Husberg B, Gonwa T, Klintmalm G. De Novo Hepatitis B infection after liver transplantation: source of disease, incidence, and impact. *Liver Transplant Surg* 1998; 4(2):119-27.
12. Testa G, Goldstein R, **Netto GJ**, Abbasoglu O, Jeyarajah R, Brooks B, Levy M, Husberg B, Gonwa T, Klintmalm G. Long-term outcome of patients transplanted with livers from Hepatitis C-positive donors. *Transplantation* 1998; 65(7):925-9.
13. Travis D, Fabia R, **Netto GJ**, Husberg B, Goldstein R, Klintmalm G, Levy M. Protection by cyclosporine A against normothermic liver ischemia-reperfusion in pigs. *J Surg Res* 1998;75(2):116- 26.
14. Jeyarajah D, **Netto GJ**, Lee SP, Testa G, Abbasoglu O, Husberg BS, Levy MF, Goldstein R, Gonwa TA, Tillery G, Crippin JS, Klintmalm GB. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? *Transplantation* 1998; 66:1300-6.
15. Bell D, Chomarat P, Broyles D, **Netto GJ**, Moumneh G, Lebecque S, Valladeau J, Davoust J, Palucka K, Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. *J Exp Med* 1999; 190(10):1417-25.
16. Testa G, Crippin JS, **Netto GJ**, Goldstein RM, Jennings LW, Brkic BS, Brooks BK, Levy MF, Gonwa TA, Klintmalm GB. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. *Liver Transpl* 2000; 6(5):553-61.
17. Tong AW, Seamour B, Chen J, Su D, Ordonez G, Frase L, **Netto GJ**, Stone MJ. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. *Leuk Lymphoma*. 2000; 36(5- 6):543-58.
18. Levy MF, Crippin J, Sutton S, **Netto GJ**, McCormack J, Curiel T, Goldstein RM, Newman JT, Gonwa TA, Banchereau J, Diamond LE, Byrne G, Logan J, Klintmalm GB. Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus. *Transplantation*. 2000; 69:272-80.
19. Högenauer C, Meyer RL, **Netto GJ**, Bell D, Little KH, Ferries L, Santa Ana CA, Porter JL, Fordtran JS. Malabsorption due to cholecystikinin deficiency in a patient with autoimmune polyglandular syndrome type I. *N Engl J Med* 2001; 344(4):270-4.

20. Tong AW, Papayoti MH, **Netto GJ**, Armstrong DT, Ordonez G, Lawson JM, Stone MJ. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. *Clin Cancer Res* 2001; 7(3):691-703.
21. Nemunaitis J, Cunningham C, Buchanan A, Edelman G, Maples P, **Netto GJ**, Tong A, Randlev B, Olson S, Kim D. Intravenous infusion of Replication-Selective (ONYX-15) in cancer patients: safety, feasibility and biological activity. *Gene Ther* 2001; 8(10):746-59.
22. Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, **Netto GJ**, Klintmalm GB, Stone MJ. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. *Transplantation* 2002; 74(8):1090-5.
23. Fasola CG, **Netto GJ**, Jennings LW, Christensen LL, Molmenti EP, Sanchez EQ, Levy MF, Goldstein RM, Klintmalm GB. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. *Transplant Proc* 2002; 34(5):1563-4.
24. Fasola CG, **Netto GJ**, Christensen LL, Molmenti EP, Sanchez EQ, Levy MF, Goldstein RM, Klintmalm GB. Delay of hepatitis C recurrence in liver transplant recipients: impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction. *Transplant Proc* 2002; 34(5):1561-2.
25. Molmenti EP, **Netto GJ**, Murray NG, Smith DM, Molmenti H, Crippin JS, Hoover TC, Jung G, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, Fasola CG, Gonwa TA, Klintmalm GB. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. *Liver Transpl* 2002; 8(6):519-26.
26. Ganaraj A, Kuhn JA, Jones RC, Grant MD, Andrews VR, Knox SM, **Netto GJ**, Altrabulsi B, Livingston SA, McCarty TM. Predictors for nonsentinel node involvement in breast cancer patients with micro-metastases in the sentinel lymph node. *Proc (Bayl Univ Med Cent)* 2003; 16(1):3-6.
27. Smith D, Agura E, **Netto GJ**, Collins R, Molmenti E, Levy M, Goldstein R, Fasola C, Christensen L, Baker J, Altrabulsi B, Osowski L, McCormack J, Fichtel L, Dawson B, Domiati-Saad R, Stone M, Klintmalm G. Liver transplant associated graft versus host disease. *Transplantation* 2003; 75(1):118- 26.
28. Nemunaitis J, Cunningham C, Tong AW, Post L, **Netto GJ**, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. *Cancer Gene Ther* 2003; 10(5):341-52.
29. Onaca NN, Levy MF, **Netto GJ**, Sanchez EQ, Chinnakotla S, Fasola C, Weinstein JS, Murray N, Goldstein RM, Klintmalm GB. Pretransplant MELD Score as a predictor of outcome after liver transplantation for chronic Hepatitis C. *Am J of Transplant* 2003; 3(5):626-30.
30. Sanchez EQ, Levy MF, Goldstein RM, Fasola CG, Tillery GW, **Netto GJ**, Watkins DL, Weinstein JS, Murray NG, Byers D, Christensen LL, Klintmalm GB. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. *Transplantation* 2003; 76(11):1583-8.
31. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, **Netto GJ**, Alonzo J, Garcia-Kennedy R, Rayón JM, Wright TL. A model to predict severe HCV-related disease following live transplantation. *Hepatology* 2003; 38(1):34-41.
32. Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, Adair D, Radkowski M, Kibler KV, Nowicki M, Douglas D, Williams J, **Netto GJ**, Mulligan D, Klintmalm G, Rakela J, Vargas HE. Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. *J Infect Dis* 2004; 189(11):2037-46.

33. Islas-Ohlmayer M, Padgett-Thomas A, Saad R, Melkus M, Cravens P, Martin M, **Netto GJ**, Garcia JV. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein- Barr virus. *J Virol* 2004; 78(24):13891-900.
34. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, **Netto GJ**, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma- differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. *Mol Ther* 2005; 11(1):160-72.
35. Onaca N, Sanchez EQ, Melton LB, **Netto GJ**, Glastad KA, Martin PA, Ueno T, Levy MF, Goldstein RM, Klintmalm GB. Cadaveric orthotopic auxiliary split liver transplantation and kidney transplantation: an alternative for type 1 primary hyperoxaluria. *Transplantation* 2005; 80(3):421-4.
36. May S, **Netto GJ**, Saad R, Kasper C. Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination: a study of two patients. *J Am Acad Dermatol* 2005; 53(3):512-516.
37. Domiati-Saad R, Klintmalm G, **Netto GJ**, Agura ED, Chinnakotla S, Smith DM. Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism. *Am J Transplant* 2005; 5(12):2968-73
38. Sanchez S, Holmes H, Katabi N, Newman J, Domiati-Saad R, Stone M, **Netto GJ**. Composite lymphocyte-rich Hodgkin lymphoma and peripheral T-cell lymphoma associated with Epstein-Barr virus: a case report and review of the literature. *Arch Pathol Lab Med* 2006; 130(1):107-12.
39. **Netto GJ**, Watkins DL, Williams JW, Colby T, dePetris G, Sharkey F, Corless C, Lewin D, Petrovic L, Sharma S, Kanel G, Theise N, West AB, Koehler A, Jhala N, Lefkowitz J, Lezzoni J, Jennings L, Tillery GW, Klintmalm G, the Hepatitis C 3 Trial Group. Interobserver agreement in Hepatitis C grading and staging and Banff grading schema for acute cellular rejection: the "Hepatitis C 3" Multi- institutional trial experience. *Arch Pathol Lab Med* 2006; 130(8):1157-62.
40. **Netto GJ**, Altrabulsi B, Katabi N, Martin P, Burt K, Levy M, Sanchez E, Watkins DL, Jennings L, Klintmalm G, Goldstein R. Radio frequency ablation of hepatocellular carcinoma prior to liver transplantation: A histologic and 'TUNEL' study. *Liver Int* 2006; 26(6):746-71.
41. Ueno T, Barri YM, **Netto GJ**, Martin A, Onaca N, Sanchez EQ, Chinnakotla S, Randall HB, Dawson S, Levy MF, Goldstein RM, Klintmalm GB. Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. *Transplantation*. 2006; 82(4):501-7.
42. **Netto GJ**, Epstein JI. Widespread high-grade prostatic intraepithelial neoplasia on prostatic needle biopsy: a significant likelihood of subsequently diagnosed adenocarcinoma. *Am J Surg Pathol* 2006; 30(9):1184-8.
43. Kuhn E, De Anda J, Manoni S, **Netto GJ**, Rosai J. Renal cell carcinoma associated with prominent angioleiomyoma-like proliferation: report of five cases and review of the literature. *Am J Surg Pathol* 2006; 30(11):1361-72.
44. Martin AP, Goldstein RM, Dempster J, **Netto GJ**, Katabi N, Derrick HC, Altrabulsi B, Jennings LW, Ueno T, Chinnakotla S, Dawson S, Randall HB, Levy MF, Onaca N, Sanchez EQ, Orr D, Klintmalm GB. Radiofrequency thermal ablation of hepatocellular carcinoma before liver transplantation - a clinical and histological examination. *Clin Transplant* 2006; 20(6):695-705.
45. Chinnakotla S, Smith DM, Domiati-Saad R, Agura ED, Watkins DL, **Netto GJ**, Uemura T, Sanchez EQ, Levy M, Klintmalm G. Acute graft-versus-host disease after liver transplantation:

- role of withdrawal of immunosuppression in therapeutic management. *Liver Transplant* 2007; 13(1):157-61.
46. Hansel DE, DeMarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, Partin AW, and **Netto GJ**. Early prostate cancer antigen expression in predicting presence of prostate cancer among men with histologically negative biopsies. *J Urol* 2007; 177(5):1736-40.
 47. Owens C, Epstein JI and **Netto GJ**. Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry. *Arch Pathol Lab Med* 2007; 131(4):599-603.
 48. Gilliland GD, Gilliland G, Fincher T, Harrington J, Gilliland JM, **Netto GJ**, Burt K. Timing of return to normal activities after orbital floor fracture repair. *Plast Reconstr Surg* 2007; 120(1):245-51.
 49. Paulson KE, Rieger-Christ K, McDevitt MA, Kuperwasser C, Kim J, Unanue VE, Zhang X, Hu M, Ruthazer R, Berasi SP, Huang CY, Giri D, Kaufman S, Dugan JM, Blum J, **Netto GJ**, Wazer DE, Summerhayes IC, Yee AS. Alterations of the HBP1 Transcriptional Repressor are associated with invasive breast cancer. *Cancer Res* 2007; 67(13):6136-45.
 50. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, **Netto GJ**, Katz E. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. *Liver Transpl* 2007; 13(11):1521-31.
 51. Grosso JF, Kelleher CC, Timothy J. Harris TJ, Maris CH, Hipkiss EL, DeMarzo A, Anders R, **Netto GJ**, Getnet D, Bruno TB, Goldberg MV, Pardoll DM, Drake CG. LAG-3 regulates CD8⁺ T cell accumulation and effector function in murine self- and tumor-tolerance systems. *J Clin Invest* 2007; 117(11):3383-92.
 52. Osunkoya AO, **Netto GJ**, Epstein JI. Colorectal adenocarcinoma involving the prostate: report of 9 cases. *Hum Pathol* 2007; 38(12):1836-41.
 53. Lane Z, Epstein JI, Ayub S, **Netto GJ**. Prostatic adenocarcinoma in colorectal biopsy: clinical and pathologic features. *Hum Pathol* 2008; 39(4):543-9.
 54. Osunkoya AO, Hansel DE, Sun X, **Netto GJ**, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. *Am J Surg Pathol* 2008; 32(3):461-7.
 55. Sireci AN, Rodriguez R, Swierczynski SL, **Netto GJ**, Argani, P. Fat-predominant mixed epithelial stromal tumor (MEST): report of a unique case mimicking angiomyolipoma. *Int J Surg Pathol* 2008; 16(1):73-7.
 56. Nagpal JK, Dasgupta S, Jadallah S, Chae YK, Ratovitski EA, Toubaji A, **Netto GJ**, Eagle T, Nissan A, Sidransky D, Trink B. Profiling the expression pattern of GPI transamidase complex subunits in human cancer. *Mod Pathol* 2008; 21(8):979-91.
 57. Loyo M, Pai SI, **Netto GJ**, Tunkel DE. Aggressive recurrent respiratory papillomatosis in a neonate. *Int J Pediatr Otorhinolaryngol* 2008; 72(6):917-20.
 58. Argani P, **Netto GJ**, Parwani AV. Papillary renal cell carcinoma with low-grade spindle cell foci: a mimic of mucinous tubular and spindle cell carcinoma. *Am J Surg Pathol*. 2008; 32(9):1353-9.
 59. Goodwin AC, Jadallah S, Toubaji A, Lecksell K, Hicks J, Kowalski J, Bova GS, De Marzo AM, **Netto GJ**, Casero RA Jr. Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. *Prostate* 2008; 68(7):766-72.
 60. **Netto GJ**, Nakai Y, Nakayama M, Jadallah S, Toubaji A, Nonomura N, Albadine R, Hicks J, Epstein JI, Yegnasubramanian S, Nelson WG, and De Marzo AM. Global DNA

- hypomethylation in intratubular germ cell neoplasia and seminoma, but not in non-seminomatous male germ cell tumors. *Mod Pathol* 2008; 21(11):1337-44.
61. Klock C, Gomes R, João M, **Netto GJ**. Prostate melanosis associated with acinar adenocarcinoma. *Int J Surg Pathol* 2008; Dec 18. [Epub ahead of print]
 62. Cheung WL, Albadine R, Chan T, Sharma R, **Netto GJ**. Phosphorylated H2AX in non-invasive low grade urothelial carcinoma of urinary bladder: Correlation with tumor recurrence. *J Urol* 2009; 181(3):1387-92.
 63. Lotan TL, Toubaji A, Albadine R, Latour M, Herawi M, Meeker AK, DeMarzo AM, Platz EA, Epstein JI, **Netto GJ**. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. *Mod Pathol* 2009; 22(3):359-65.
 64. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, **Netto GJ**, Lerner SP, Sagalowsky AI, Shariat SF. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. *J Natl Cancer Inst* 2009; 101(2):114-9.
 65. Albadine R, Wang W, Brownlee NA, Toubaji A, Billis A, Epstein JI, Argani P, Garvin AJ, Couzi R, Schaeffer E, Pavlovich CP, **Netto GJ**. Topoisomerase IIA status in renal medullary carcinoma: immunoexpression and gene copy alterations of a potential target of therapy. *J Urol* 2009;182(2):735-40.
 66. Wang W, Tavora F, Sharma R, Eisenberger M and **Netto GJ**. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. *Urol Oncol* 2009; 27(5):525-8.
 67. Fujita K, Pavlovich CP, **Netto GJ**, Konishi Y, Isaacs WB, Ali S, De Marzo AM, Meeker AK. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. *Hum Pathol* 2009; 40(7):924-33.
 68. Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, Pan CC, **Netto GJ**, Doglioni C, Hes O, Argani P, Chilosì M. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. *Mod Pathol* 2009; 22(8):1016-22.
 69. Osunkoya AO, Young AN, Wang W, **Netto GJ**, Epstein JI. Comparison of gene expression profiles in tubulocystic carcinoma and collecting duct carcinoma of the kidney. *Am J Surg Pathol* 2009; 33(7):1103-6.
 70. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, **Netto GJ**, Anders R, Pardoll DM, Drake CG. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. *Cancer Res* 2009; 9(10):4309-18.
 71. Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, **Netto GJ**, Lerner SP, Sagalowsky AI, Cote RJ. p53 predictive value for pT1-2 N0 disease at radical cystectomy. *J Urol* 2009; 182(3):907-13.
 72. Albadine R, Latour M, Toubaji A, Haffner M, Isaacs WB, A Platz E, Meeker AK, Demarzo AM, Epstein JI, **Netto GJ**. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. *Mod Pathol* 2009; 22(11):1415-22.
 73. Leman ES, Magheli A, Yong KM, **Netto GJ**, Hinz S, Getzenberg RH. Identification of nuclear structural protein alterations associated with seminomas. *J Cell Biochem* 2009; 108(6):1274-9.
 74. Verheul HM, van Erp K, Homs MY, Yoon GS, van Der Groep P, Rogers C, Hansel DE, **Netto GJ**, Pili R. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. *Urology* 2010; 75(3):608-14.

75. D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, **Netto GJ**, Getzenberg RH. Extracellular matrix associated protein CYR61 is linked to prostate cancer development. *J Urol* 2010; 183(4):1604-10.
76. Lee TK, Chuang ST, **Netto GJ**. Conventional prostatic adenocarcinoma arising in a multilocular prostatic cystadenoma. *Pathol Int* 2010; 60(5):413-6.
77. Albadine R, Schultz L, Illei P, Ertoy D, Hicks J, Sharma R, Epstein JI, **Netto GJ**. PAX8 (+)/p63 (-) Immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. *Am J Surg Pathol* 2010; 34(7):965-9.
78. Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo D, Lee T, Epstein JI, **Netto GJ**. Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a Post- WHO/ISUP Classification Cohort from a single academic center. *Arch Pathol Lab Med* 2010; 134(8):1160-3.
79. Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, **Netto GJ**, Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to Sunitinib in patients with renal cell carcinoma: evidence from a Xenograft study. *Mol Cancer Ther* 2010;9(6):1525-35. Armstrong AJ, **Netto GJ**, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA. A pharmacodynamic study of rapamycin in men with intermediate- to high- risk localized prostate cancer. *Clin Cancer Res* 2010; 16(11):3057-66.
80. Schaeffer EM, Guzzo TJ, Furge KA, **Netto GJ**, Westphal M, Dykema K, Yang X, Zhou M, Teh BT, Pavlovich CP. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. *BJU Int* 2010; Jul;106(1):62-5.
81. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen Y-B, Neilsen ME, Gonzalzo ML, Sidransky D, Schoenberg M, **Netto GJ**. Expression status and prognostic significance of mTOR pathway members in urothelial carcinoma of urinary bladder following cystectomy. *Cancer* 2010; Dec 1;116(23):5517-26.
82. Argani P, Aulmann S, Illei PB, **Netto GJ**, Ro J, Cho H, Dogan S, Ladanyi M, Martignoni G, Weiss SW. A distinctive subset of pecomas harbors TFE3 gene fusions. *Am J Surg Pathol* 2010; Oct;34(10):1395-406.
83. Argani P, Hicks J, De Marzo AM, Albadine R, Illei PB, Ladanyi M, Reuter VE and **Netto GJ**. Xp11 Translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. *Am J Surg Pathol* 2010; Sep;34(9):1295-303.
84. **Netto GJ**, Eisenberger M, Epstein JI; TAX 3501 Trial Investigators. Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: findings of TAX 3501 multinational clinical trial. *Urology* 2010; May;77(5):1155-60.
85. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, **Netto GJ**, De Marzo AM, Nelson WG, Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. *Nat Genet* 2010;42(8):668-75.
86. Magheli A, Gonzalzo ML, Su LM, Guzzo TJ, **Netto GJ**, Humphreys EB, Han M, Partin AW, Pavlovich CP. Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. *BJU Int* 2011; Jun;107(12):1956-62.

87. Sidana A, Wang M, Chowdhury WH, Toubaji A, Shabbeer S, **Netto GJ**, Carducci M, Lupold SE, Rodriguez R. Does valproic acid induce neuroendocrine differentiation in prostate cancer? *J Biomed Biotechnol* 2011; 607480.
88. Ellis C, Banerjee P, Carney E, Sharma R and **Netto GJ**. Adrenal Lymphangioma: clinicopathologic and immunohistochemical characteristics of a rare lesion. *Hum Pathol* 2011; Jul;42(7):1013-8. Epub 2011 Feb 11.
89. Carney E, Banerjee P, Ellis CL, Albadine R, Sharma R, Burger P , Chaux A and **Netto GJ**. PAX2(-)/PAX8(-)/Inhibin A(+) immunoprofile in hemangioblastoma: a helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. *Am J Surg Pathol* 2011;35(2):262-267.
90. D'Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA, **Netto GJ**, Getzenberg RH. Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. *Clin Cancer Res* 2010; 16(23):5908-5913.
91. LeBron C, Pal P, Brait M, Dasgupta S, Guerrero-Preston R, Looijenga LH, Kowalski J, **Netto GJ**, Hoque MO. Genome-wide analysis of genetic alterations in testicular primary seminoma using high resolution single nucleotide polymorphism arrays. *Genomics* 2011; Jun;97(6):341-9.
92. Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, **Netto GJ**, Gonzalzo ML. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. *Urol Oncol* 2011 Mar 9. [Epub ahead of print]
93. Chaux A, Pfannl R, Rodríguez IM, Barreto JE, Velazquez EF, Lezcano C, Piris A, **Netto GJ**, Cubilla AL. Distinctive immunohistochemical profile of penile intraepithelial lesions: a study of 74 cases. *Am J Surg Pathol* 2011; Apr;35(4):553-62.
94. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, **Netto GJ**. ERG gene rearrangements are common in prostatic small cell carcinomas. *Mod Pathol* 2011; Jun;24(6):820-8.
95. Cimino-Mathews A, Sharma R, **Netto GJ**. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid. *Am J Surg Pathol* 2011; May;35(5):757-61.
96. Brimo F, Herawi M, Sharma R, **Netto GJ**, Epstein JI, Illei PB. Hepatocyte nuclear factor-1 β expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis. *Hum Pathol* 2011; Nov;42(11):1613-9.
97. Ling S, Chang X, Schultz L, Lee TK, Chaux A, Marchionni L, **Netto GJ**, Sidransky D, Berman DM. An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. *Cancer Res* 2011; Jun;71(11):38212-21.
98. Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D, Pea M, Bonetti F, Illei PB, **Netto GJ**, Ladanyi M, Chilosi M, Argani P. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. *Mod Pathol* 2011; Oct;24(10):1313-9.
99. Elwood H, Chaux A, Schultz L, Illei PB, Baydar DE, Billis A, Sharma R, Argani P, Epstein JI, **Netto GJ**. Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma. *Urology* 2011; Aug;78(2):474.e1-5.
100. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, **Netto GJ**. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. *Am J Surg Pathol* 2011; Jul;35(7):1014-20.
101. Buadi F, Hsing AW, Katzmann JA, Pfeiffer RM, Waxman A, Yeboah ED, Biritwum RB, Tettey Y, Adjei A, Chu LW, Demarzo A, **Netto GJ**, Dispenzieri A, Kyle RA, Rajkumar SV, Landgren

- O. High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa. *Am J Hematol* 2011 Jul;86(7):554-8.
102. Chaux A, Eifler J, Karram S, Al-Hussain T, Faraj S, Pomper M, Rodriguez R, **Netto GJ**. Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques. *Urol Oncol* 2011; Jun 1. [Epub ahead of print]
 103. Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM, **Netto GJ**, Pardoll DM, Drake CG. Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. *Prostate*. 2012 Apr;72(5):514-22. doi:10.1002/pros.21453. Epub 2011 Jul 14. PubMed PMID: 21761425; PubMed Central
 104. Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, **Netto GJ**. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. *Mod Pathol* 2011; Nov;24(11):1511-20.
 105. Lee TK, Chaux A, Karram S, Miyamoto H, Miller JS, Fajardo DA, Epstein JI, **Netto GJ**. Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. *Hum Pathol* 2011; Nov;42(11):1799-803.
 106. Albadine R, Hyndman ME, Chaux A, Jeong JY, Saab S, Tavora F, Epstein JI, Gonzalgo ML, Pavlovich CP, **Netto GJ**. Characteristics of positive surgical margins in robotic assisted radical prostatectomy, open retropubic radical prostatectomy, and laparoscopic radical prostatectomy: a comparative histopathologic study from a single academic center. *Hum Pathol*. 2012 Feb;43(2):254-60. Epub 2011 Aug 4. PubMed PMID: 21820147.
 107. Chaux A, Karram S, Miller JS, Fajardo DA, Lee TK, Miyamoto H, **Netto GJ**. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification cohort from a single academic center. *Hum Pathol* 2012; Jan;43(1):115-20.
 108. Schultz L, Chaux A, Albadine R, Hicks J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers H, Argani P, Reuter VE, **Netto GJ**. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. *Am J Surg Pathol* 2011; Oct;35(10):1549-56.
 109. Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, **Netto GJ**, Yeh S. Expression of androgen and estrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. *BJU Int*. 2012 Jun;109(11):1716-26. doi: 10.1111/j.1464-410X.2011.10706.x. Epub 2012 Jan 5. PubMed PMID: 22221549.
 110. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, **Netto GJ**, De Marzo AM, Yegnasubramanian S. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. *Oncotarget* 2011; Aug;2(8):627-37.
 111. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, **Netto GJ**, Epstein JI, Lotan TL, Westra WH, Shih IM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, De Marzo AM, Terracciano L, Torbenson M, Meeker AK. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. *Am J Pathol* 2011; Oct;179(4):1608-15.
 112. Lotan T, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks J, Park B, Humphreys E, Partin A, Han M, **Netto GJ**, Isaacs WB, De Marzo AM. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. *Clin Cancer Res* 2011; Oct 15;17(20):6453-73.

113. Klintmalm GB, Davis GL, Teperman L, **Netto GJ**, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized multicenter study comparing steroid-free and standard immunosuppression for liver transplant recipients with chronic hepatitis C. *Liver Transpl* 2011; Dec;17(12):1394-403.
114. Karram S, Trock BJ, **Netto GJ**, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. *Am J Surg Pathol* 2011; Sep;35(9):1351-5.
115. Karafin M, Parwani AV, **Netto GJ**, Illei PB, Epstein JI, Ladanyi M, Argani P. Diffuse expression of PAX2 and PAX8 in the cystic epithelium of mixed epithelial stromal tumor, angiomyolipoma with epithelial cysts, and primary renal synovial sarcoma: evidence supporting renal tubular differentiation. *Am J Surg Pathol* 2011 Sep;35(9):1264-73.
116. Brait M, Malonado L, Begum s, Loyo M, Wehle D, Tavora FF, Looijenga LH, Kowalski J, Zhang Z, Rosenbaum E, Halachmi S, **Netto GJ**, Hoque MO. DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma. *Br J Cancer* 2011; Nov 8. Doi:10.1038/bjc.2011.468.
117. Chaux A, **Netto GJ**, Rodriguez IM, Barreto JE, Oertell J, Ocampos S, Boggino H, Codas R, Zavier Bosch F, de Sanjose S, Munoz N, Hildesheim A, Cubilla AL. Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. *World J Urol* 2011; Nov 25 [Epub ahead of print]
118. Chaux A, Velazquez EF, Amin A, Soskin A, Pfannl R, Rodriguez IM, Barreto JE, Lezcano C, Ayala G, **Netto GJ**, Cubilla AL. Distribution and characterization of subtypes of penile intraepithelial neoplasia and their association with invasive carcinomas: a pathological study of 139 lesions in 121 patients. *Hum Pathol*. 2012 Jul;43(7):1020-7. Epub 2011 Dec 12. PubMed PMID: 22169255.
119. Chaux A, Fajardo DA, Gonzalez-Roibon N, Partin AW, Eisenberger M, Deweese TL, **Netto GJ**. High-grade adenocarcinoma present in a single biopsy core as associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy. *Urology* 2011;79(4):863-8. PubMed PMID: 22173174; PubMed Central PMCID: PMC3449144.
120. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, **Netto GJ**, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate Tcell function to promote tumoral immune escape. *Cancer Res*. 2012 Feb 15;72(4):917-27. Epub 2011Dec 20. PubMed PMID: 22186141; PubMed Central PMCID: PMC3288154.
121. Vaughn MP, Biswal Shinohara D, Castagna N, Hicks JL, **Netto GJ**, De Marzo AM, Speed TJ, Reichert ZR, Kwabi-Addo B, Henderson CJ, Wolf CR, Yegnasubramanian S, Nelson WG. Humanizing π -class glutathione S-transferase regulation in a mouse model alters liver toxicity in response to acetaminophen overdose. *PLoS One*. 2011;6(10):e25707. Epub 2011 Oct 11. PubMed PMID: 22022436; PubMed Central PMCID: PMC3191143.
122. Chokkalingam AP, Yeboah ED, Demarzo A, **Netto GJ**, Yu K, Biritwum RB, Tettey Y, Adjei A, Jadallah S, Li Y, Chu LW, Chia D, Niwa S, Partin A, Thompson IM, Roehrborn C, Hoover RN, Hsing AW. Prevalence of BPH and lower urinary tract symptoms in West Africans. *Prostate Cancer Prostatic Dis*. 2012 Jun;15(2):170-6. doi: 10.1038/pcan.2011.43. Epub 2011 Sep 13. PubMed PMID: 21912428.

123. Sher L, Jennings L, Rudich S, Alexopoulos SP, **Netto GJ**, Teperman L, Kinkhabwala M, Brown RS Jr, Pomfret E, Klintmalm G; HCV-3 Study Group. Results of live donor liver transplantation in patients with hepatitis C virus infection: the HCV 3 trial experience. *Clin Transplant*. 2012 May;26(3):502-9. doi: 10.1111/j.1399-0012.2011.01561.x. Epub 2011 Dec 12. PubMed PMID: 22151078.
124. Malinowska I, Kwiatkowski DJ, Weiss S, Martignoni G, **Netto GJ**, Argani P. Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction. *Am J Surg Pathol*. 2012 May;36(5):783-4. PubMed PMID: 22456611; PubMed Central PMCID: PMC3327756.
125. Chaux A, Cohen JS, Schultz L, Albadine R, Jadallah S, Murphy KM, Sharma R, Schoenberg MP, **Netto GJ**. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. *Hum Pathol*. 2012; 43(10):1590-5. PubMed PMID: 22406363.
126. Rodriguez E, **Netto GJ**, Li QK. Intrapancreatic accessory spleen: A case report and review of literature. *Diagn Cytopathol*. 2012 Jan 12. doi: 10.1002/dc.22813.[Epub ahead of print] PubMed PMID: 22241738.
127. Zheng G, Chaux A, Sharma R, **Netto GJ**, Caturegli P. LMP2, a novel immunohistochemical marker to distinguish renal oncocytoma from the eosinophilic variant of chromophobe renal cell carcinoma. *Exp Mol Pathol*. 2012 Jun 12. [Epub ahead of print] PubMed PMID: 22705098.
128. Chaux A, Brimo F, Gonzalez-Roibon N, Shah S, Schultz L, Rizk JM, Argani P, Hicks J, **Netto GJ**. Immunohistochemical Evidence of Dysregulation of the Mammalian Target of Rapamycin Pathway in Primary and Metastatic Pheochromocytomas. *Urology*.2012;80(3):736.e7-12 PubMed PMID: 22698476.
129. Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, **Netto GJ**. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. *Mod Pathol*. 2012 Nov;25(11):1543-9. PubMed PMID: 22684219.
130. Miyamoto H, Izumi K, Yao JL, Li Y, Yang Q, McMahon LA, Gonzalez-Roibon N, Hicks DG, Tacha D, **Netto GJ**. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. *Hum Pathol*. 2012 Nov;43(11):2033- PubMed PMID: 22607700.
131. Toubaji A, Sutcliffe S, Chaux A, Lecksell K, Hicks J, De Marzo AM, Platz EA, **Netto GJ**. Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases. *Hum Pathol*. 2012 ;43(11):1852-65 PubMed PMID: 22554381.
132. Chaux A, Schultz L, Albadine R, Hicks J, Kim JJ, Allaf ME, Carducci MA, Rodriguez R, Hammers HJ, Argani P, Reuter VE, **Netto GJ**. Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. *Hum Pathol*. 2012 Apr 26. [Epub ahead of print] PubMed PMID: 22542128.
135. Izumi K, Li Y, Ishiguro H, Zheng Y, Yao JL, **Netto GJ**, Miyamoto H. Expression of UDP-glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen. *Mol Carcinog*. 2012 Nov 9[Epub ahead of print] PubMed PMID: 23143693.
136. Sidana A, Wang M, Shabbeer S, Chowdhury WH, **Netto GJ**, Lupold SE, Carducci M, Rodriguez R. Mechanism of growth inhibition of prostate cancer xenografts by valproic Acid. *J Biomed*

Biotechnol. 2012;2012:180363. doi: 10.1155/2012/180363. Epub 2012 Oct 2. PubMed PMID: 23093837; PubMed Central PMCID: PMC3471003.

137. Gonzalez-Roibon ND, Chaux A, Al-Hussain T, Osunkoya AO, Bezerra SM, Hicks J, Epstein JI, **Netto GJ**. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder. *Hum Pathol*. 2012 Oct 17. doi:pil: S0046-8177(12)00265-1. 10.1016/j.humpath.2012.07.009. [Epub ahead of print] PubMed PMID: 23084634.
138. Georgiades C, Rodriguez R, Azene E, Weiss C, Chaux A, Gonzalez-Roibon N, **Netto GJ**. Determination of the Nonlethal Margin Inside the Visible "Ice-Ball" During Percutaneous Cryoablation of Renal Tissue. *Cardiovasc Intervent Radiol*. 2012 Aug 30. [Epub ahead of print] PubMed PMID: 22933102.
139. Argani P, Yonescu R, Morsberger L, Morris K, **Netto GJ**, Smith N, Gonzalez N, Illei PB, Ladanyi M, Griffin CA. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin- embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. *Am J Surg Pathol*. 2012 Oct;36(10):1516-26. PubMed PMID: 22892601.
140. Chaux A, Comp erat E, Varinot J, Hicks J, Lecksell K, Solus J, **Netto GJ**. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection. *Urology*. 2013 Jan;81(1):116-22. PubMed PMID: 23273076
141. Gonzalez-Roibon N, Katz B, Chaux A, Sharma R, Munari E, Faraj SF, Illei PB, Torbenson M, **Netto GJ**. Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. *Hum Pathol*. 2013 Jan 21.[Epub ahead of print] PubMed PMID: 23347651.
142. Zheng G, Martignoni G, Antonescu C, Montgomery E, Eberhart C, **Netto GJ**, Taube J, Westra W, Epstein JI, Lotan T, Maitra A, Gabrielson E, Torbenson M, Iacobuzio-Donahue C, Demarzo A, Shih IM, Illei P, Wu TC, Argani P. A broad survey of cathepsin K immunoreactivity in human neoplasms. *Am J Clin Pathol*. 2013, Feb;139(2):151-159. PubMed PMID: 23355199.
143. Brait M, Munari E, Lebron C, Noordhuis MG, Begum S, Michailidi C, Gonzalez-Roibon N, Maldonado L, Sen T, Guerrero-Preston R, Cope L, Parrella P, Fazio VM, Ha PK, **Netto GJ**, Sidransky D, Hoque MO. Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. *Cell Cycle*. 2013 Feb 22;12(7). [Epub ahead of print] PubMed PMID:23435205.
144. Chaux A, Cubilla AL, Haffner MC, Lecksell KL, Sharma R, Burnett AL, **Netto GJ**. Combining routine morphology, p16(INK4a) immunohistochemistry, and in situ hybridization for the detection of human papillomavirus infection in penile carcinomas: A tissue microarray study using classifier performance analyses. *Urol Oncol*. 2013 Mar 13. doi:pil: S1078-1439(12)00158-5.10.1016/j.urolonc.2012.04.017. [Epub ahead of print] PubMed PMID: 23499169.
145. Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, Goldberg MV, Bruno TC, Grosso JF, Durham N, **Netto GJ**, Pardoll DM, Drake CG. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. *J Transl Med*. 2013 Apr 4;11(1):89. [Epub ahead of print] PubMed PMID: 23557194.
146. Killela PJ, Reitman ZJ, Jiao Y, Bettgowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, **Netto GJ**, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD,

- Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proc Natl Acad Sci U S A*. 2013 Mar 25. [Epub ahead of print] PubMed PMID:23530248.
147. Chaux A, Han JS, Lee S, Gonzalez-Roibon N, Sharma R, Burnett AL, Cubilla AL, **Netto GJ**. Immunohistochemical profile of the penile urethra and differential expression of GATA3 in urothelial versus squamous cell carcinomas of the penile urethra. *Hum Pathol*. 2013 Oct 14. doi:pil: S0046-8177(13)00312-2. 10.1016/j.humpath.2013.07.023. [Epub ahead of print] PubMed PMID: 24134931.
 148. Chalfin HJ, Gurda GT, Hammers HJ, **Netto GJ**, Bivalacqua TJ. Renal cell carcinoma presenting with brain metastasis from a 1.6 cm primary tumor. *Can J Urol*. 2013 Oct;20(5):6965-7. PubMed PMID: 24128841.
 149. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahlon AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, **Netto GJ**, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. *Nat Genet*. 2013 Oct 13. doi: 10.1038/ng.2800. [Epub ahead of print] PubMed PMID: 24121789.
 150. Papadopoulos N, Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg MP, Bivalacqua T, Allaf ME, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, **Netto GJ**. TERT Promoter Mutations Occur Early in Urothelial Neoplasia and are Biomarkers of Early Disease and Disease Recurrence in Urine. *Cancer Res*. 2013 Oct 11. [Epub ahead of print] PubMed PMID: 24121487.
 151. Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, **Netto GJ**, Trock BJ, De Marzo AM, Sfanos KS. Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. *Prostate*. 2013 Sep 21. doi: 10.1002/pros.22730. [Epub ahead of print] PubMed PMID: 24115205.
 152. Chaux A, Munari E, Katz B, Sharma R, Lecksell K, Cubilla AL, Burnett AL, **Netto GJ**. The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. *Hum Pathol*. 2013 Sep 25. doi:pil: S0046-8177(13)00299-2. 10.1016/j.humpath.2013.07.012. [Epub ahead of print] PubMed PMID: 24075601.
 153. Munari E, Fujita K, Faraj S, Chaux A, Gonzalez-Roibon N, Hicks J, Meeker A, Nonomura N, **Netto GJ**. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. *Hum Pathol*. 2013 Sep 27. doi:pil:S0046-8177(13)00295-5. 10.1016/j.humpath.2013.07.008. [Epub ahead of print] PubMed PMID: 24074531.
 154. Gonzalez-Roibon N, Albadine R, Sharma R, Faraj SF, Illei PB, Argani P, Ertoy D, Allaf ME, **Netto GJ**. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas. *Hum Pathol*. 2013 Sep 24. doi:pil: S0046-8177(13)00293-1. 10.1016/j.humpath.2013.07.006. [Epub ahead of print] PubMed PMID: 24071011.
 155. Gurda GT, Vandenbussche CJ, Yonescu R, Gonzalez-Roibon N, Ellis CL, Batista DA, **Netto GJ**. Sacrococcygeal teratomas: clinico-pathological characteristics and isochromosome 12p status. *Mod Pathol*. 2013 Sep 20. doi: 10.1038/modpathol.2013.171. [Epub ahead of print] PubMed PMID: 24051698.
 156. Faraj SF, Albadine R, Chaux A, Gonzalez-Roibon N, Hicks J, Humphreys E, Partin A, **Netto GJ**. Activation of Mammalian Target of Rapamycin Signaling Pathway Markers in Minute Adenocarcinoma of the Prostate. *Urology*. 2013 Sep 11. doi:pil: S0090-4295(13)00893-5. 10.1016/j.urology.2013.07.028. [Epub ahead of print] PubMed PMID: 24035134.

157. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, **Netto GJ**, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel. Renal tumors: diagnostic and prognostic biomarkers. *Am J Surg Pathol*. 2013 Oct;37(10):1518-31. doi: 10.1097/PAS.0b013e318299f12e. PubMed PMID: 24025522.
158. Chaux A, Albadine R, Schultz L, Hicks J, Carducci MA, Argani P, Allaf M, **Netto GJ**. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. *Hum Pathol*. 2013 Oct;44(10):2323-30. doi: 10.1016/j.humpath.2013.05.014. Epub 2013 Aug 15. PubMed PMID: 23953228.
159. Green WM, Yonescu R, Morsberger L, Morris K, **Netto GJ**, Epstein JI, Illei PB, Allaf M, Ladanyi M, Griffin CA, Argani P. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. *Am J Surg Pathol*. 2013 Aug;37(8):1150-63. doi: 10.1097/PAS.0b013e31828a69ae. PubMed PMID: 23715164.
160. Fahmy M, Mansure JJ, Brimo F, Yafi FA, Segal R, Althunayan A, Hicks J, Meeker A, **Netto GJ**, Kassouf W. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. *Hum Pathol*. 2013 Sep;44(9):1766-72. PubMed PMID: 23623586.
161. González-Roibón N, Han JS, Lee S, Feng Z, Arslankoz S, Smith N, Pierorazio PM, Humphreys E, Deweese TL, Partin AW, Bivalacqua TJ, Han M, Trock B, **Netto GJ**. Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancer. *Int J Surg Pathol*. 2013 Aug;21(4):352-7. PubMed PMID:23564700.
162. Raman SP, Johnson PT, Allaf ME, **Netto GJ**, Fishman EK. Chromophobe renal cell carcinoma: multiphase MDCT enhancement patterns and morphologic features. *AJR Am J Roentgenol*. 2013 Dec;201(6):1268-76. doi: 10.2214/AJR.13.10813. PubMed PMID: 24261366.
163. Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, Epstein JI, **Netto GJ**, Argani P. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. *Mod Pathol*. 2014 Jun;27(6):875-86. doi: 10.1038/modpathol.2013.208. Epub 2013 Dec 6. PubMed PMID: 24309327.
164. Gonzalez-Roibon N, Faraj SF, Munari E, Bezerra SM, Albadine R, Sharma R, Argani P, Allaf ME, **Netto GJ**. Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. *Hum Pathol*. 2014 Feb;45(2):244-8. doi: 10.1016/j.humpath.2013.08.020. Epub 2013 Dec 4. PubMed PMID: 24315206.
165. Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, **Netto GJ**, Liu W, Isaacs WB, De Marzo AM, Lotan TL. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. *Clin Cancer Res*. 2014 Feb 15;20(4):890-903. doi: 10.1158/1078-0432.CCR-13-1982. Epub 2013 Dec 9. PubMed PMID: 24323898; PubMed Central PMCID: PMC3931005.
166. Bettgowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, **Netto GJ**, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih IM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. PubMed PMID: 24553385; PubMed Central PMCID: PMC4017867.

167. Rodić N, Sharma R, Sharma R, Zampella J, Dai L, Taylor MS, Hruban RH, Iacobuzio-Donahue CA, Maitra A, Torbenson MS, Goggins M, Shih leM, Duffield AS, Montgomery EA, Gabrielson E, **Netto GJ**, Lotan TL, De Marzo AM, Westra W, Binder ZA, Orr BA, Gallia GL, Eberhart CG, Boeke JD, Harris CR, Burns KH. Long interspersed element-1 protein expression is a hallmark of many human cancers. *Am J Pathol.* 2014 May;184(5):1280-6. doi: 10.1016/j.ajpath.2014.01.007. Epub 2014 Mar 6. PubMed PMID: 24607009; PubMed Central PMCID: PMC4005969.
168. Chaux A, Munari E, Cubilla AL, Hicks J, Lecksell K, Burnett AL, **Netto GJ**. Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases. *Histopathology.* 2014 May;64(6):863-71. doi: 10.1111/his.12338. Epub 2014 Feb 24. PubMed PMID: 24279699.
169. Smith NE, Illei PB, Allaf M, Gonzalez N, Morris K, Hicks J, Demarzo A, Reuter VE, Amin MB, Epstein JI, **Netto GJ**, Argani P. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. *Am J Surg Pathol.* 2014 May;38(5):604-14. doi: 10.1097/PAS.0000000000000203. PubMed PMID: 24618616.
170. Smith NE, Deyrup AT, Mariño-Enriquez A, Fletcher JA, Bridge JA, Illei PB, **Netto GJ**, Argani P. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? *Am J Surg Pathol.* 2014 Jun;38(6):858-63. doi: 10.1097/PAS.0000000000000179. PubMed PMID: 24698962
171. Munari E, Marchionni L, Chitre A, Hayashi M, Martignoni G, Brunelli M, Gobbo S, Argani P, Allaf M, Hoque MO, **Netto GJ**. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. *Hum Pathol.* 2014 Jun;45(6):1130-8. doi: 10.1016/j.humpath.2014.01.013. Epub 2014 Jan 31. PubMed PMID: 24703100.
172. Gonzalez-Roibon N, Kim JJ, Faraj SF, Chaux A, Bezerra SM, Munari E, Ellis C, Sharma R, Keizman D, Bivalacqua TJ, Schoenberg M, Eisenberger M, Carducci M, **Netto GJ**. Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy. *Urology.* 2014 Jun;83(6):1444.e1-6. doi: 10.1016/j.urology.2014.01.028. Epub 2014 Apr 6. PubMed PMID: 24713135.
173. Hsing AW, Yeboah E, Biritwum R, Tettey Y, De Marzo AM, Adjei A, **Netto GJ**, Yu K, Li Y, Chokkalingam AP, Chu LW, Chia D, Partin A, Thompson IM, Quraishi SM, Niwa S, Tarone R, Hoover RN. High Prevalence of Screen Detected Prostate Cancer in West Africans: Implications for Racial Disparity of Prostate Cancer. *J Urol.* 2014 Apr 18. pii: S0022-5347(14)03345-X. doi: 10.1016/j.juro.2014.04.017. [Epub ahead of print] PubMed PMID: 24747091.
174. Maldonado L, Brait M, Loyo M, Sullenberger L, Wang K, Peskoe SB, Rosenbaum E, Howard R, Toubaji A, Albadine R, **Netto GJ**, Hoque MO, Platz EA, Sidransky D. GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. *J Urol.* 2014 Apr 21. pii: S0022-5347(14)03413-2. doi: 10.1016/j.juro.2014.04.082. [Epub ahead of print] PubMed PMID: 24769028.
175. Chung CC, Hsing AW, Edward Yeboah, Biritwum R, Tettey Y, Adjei A, Cook MB, De Marzo A, **Netto GJ**, Tay E, Boland JF, Yeager M, Chanock SJ. A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestry. *Prostate.* 2014 May;74(6):579-89. PubMed PMID: 24783269.
176. Hayashi M, Bernert H, Kagohara LT, Maldonado L, Brait M, Schoenberg M, Bivalacqua T, **Netto GJ**, Koch W, Sidransky D, Hoque MO. Epigenetic inactivation of VGF associated with

- Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. *Oncotarget*. 2014 May 30;5(10):3350-61. PubMed PMID: 24830820.
177. Bezerra SM, Lotan TL, Faraj SF, Karram S, Sharma R, Schoenberg M, Bivalacqua TJ, **Netto GJ**. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. *Hum Pathol*. 2014 Apr 24. pii: S0046-8177(14)00164-6. doi: 10.1016/j.humpath.2014.04.011. [Epub ahead of print] PubMed PMID: 24925221.
 178. Arora V, Schwartz G, Tilson MP, **Netto GJ**, Mandal K. A Right Atrial Mass: "More Than Meets the Eye". *J Clin Oncol*. 2014 Jun 23. pii: JCO.2013.49.3130. [Epub ahead of print] PubMed PMID: 24958822
 179. Ball MW, Bezerra SM, Gorin MA, Cowan M, Pavlovich CP, Pierorazio PM, **Netto GJ**, Allaf ME. Grade Heterogeneity in Small Renal Masses: Potential Implications for Renal Mass Biopsy. *J Urol*. 2014 Jun 21. pii: S0022-5347(14)03826-9. doi:10.1016/j.juro.2014.06.067. [Epub ahead of print] PubMed PMID: 24960470.
 180. Reese AC, Ball MW, Gandhi N, Gorin MA, **Netto GJ**, Bivalacqua TJ, Schoenberg MP. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. *Urology*. 2014 Aug;84(2):358-63. doi: 10.1016/j.urology.2014.03.040. PubMed PMID: 25065987.181.
 181. Brennen WN, Rosen DM, Chaux A, **Netto GJ**, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. *Prostate*. 2014 Sep;74(13):1308-19. doi: 10.1002/pros.22847. Epub 2014 Jul 22. PubMed PMID: 25053236; PubMed Central PMCID: PMC4130904.
 182. Munari E, Chaux A, Maldonado L, Compérat E, Varinot J, Bivalacqua TJ, Hoque MO, **Netto GJ**. Cyclin A1 Expression Predicts Progression in pT1 Urothelial Carcinoma of Bladder: A Tissue Microarray Study of 149 Patients Treated by Transurethral Resection. *Histopathology*. 2015 Jan;66(2):262-9. doi: 10.1111/his.12499. Epub 2015 Jan 7. PubMed PMID: 25039670
 183. Reese AC, Johnson PT, Gorin MA, Pierorazio PM, Allaf ME, Fishman EK, **Netto GJ**, Pavlovich CP. Pathological characteristics and radiographic correlates of complex renal cysts. *Urol Oncol*. 2014 Oct;32(7):1010-6. doi: 10.1016/j.urolonc.2014.02.022. PubMed PMID: 25022857.
 184. Ishiguro H, Kawahara T, Zheng Y, **Netto GJ**, Miyamoto H. Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression. *Am J Clin Pathol*. 2014 Aug;142(2):157-64. doi: 10.1309/AJCPU8UCEZYG4WTV. PubMed PMID: 25015855.
 185. Maldonado L, Brait M, Michailidi C, Munari E, Driscoll T, Schultz L, Bivalacqua T, Schoenberg M, Sidransky D, **Netto GJ**, Hoque MO. An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. *Oncotarget*. 2014 Jun 23. [Epub ahead of print] PubMed PMID: 24980822.
 186. Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT, Yang XJ, Argani P, **Netto GJ**, Zhong M. High Frequency of TERT mutations in Small Cell Carcinoma of Bladder. *J Hematol Oncol*. 2014 Jul 20;7:47. doi: 10.1186/s13045-014-0047-7. PubMed PMID: 25042800; PubMed Central PMCID: PMC4223615.
 187. Bezerra SM, Chaux A, Ball MW, Faraj SF, Munari E, Gonzalez-Roibon N, Sharma R, Bivalacqua TJ, Burnett AL, **Netto GJ**. Human papillomavirus infection and immunohistochemical p16(INK4a) expression as predictors of outcome in penile squamous cell carcinomas. *Hum Pathol*. 2014 Dec 31. pii: S0046-8177(14)00511-5. doi: 10.1016/j.humpath.2014.12.004. [Epub ahead of print] PubMed PMID: 25661481.

188. Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, **Netto GJ**, Ishiguro H, Miyamoto H. Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. *Oncotarget*. 2015 Jan 8. [Epub ahead of print] PubMed PMID: 25638160.
189. Kawahara T, Kashiwagi E, Li Y, Zheng Y, Miyamoto Y, **Netto GJ**, Ishiguro H, Miyamoto H. Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. *Mol Carcinog*. 2015 Jan 15. doi: 10.1002/mc.22265. [Epub ahead of print] PubMed PMID: 25594762.
190. Michailidi C, Hayashi M, Datta S, Sen T, Zenner K, Oladeru O, Brait M, Izumchenko E, Baras A, VandenBussche C, Argos M, Bivalacqua TJ, Ahsan H, Hahn NM, **Netto GJ**, Sidransky D, Hoque MO. Involvement of epigenetics and EMT related miRNA in arsenic induced neoplastic transformation and their potential clinical use. *Cancer Prev Res (Phila)*. 2015 Jan 13. pii: canprevres.0251.2014. [Epub ahead of print] PubMed PMID: 25586904.
191. Rioux-Leclercq N, Ferran A, Mahul A, Argani P, Billis A, Bonsib S, Cheng L, Cheville J, Eble J, Egevad L, Epstein J, Grignon D, Hes O, Humphrey P, Magi-Galluzzi C, Martignoni G, McKenney J, Merino M, Moch H, Montironi R, **Netto GJ**, Reuter V, Samaratinga H, Shen S, Srigley J, Tamboli P, Tan PH, Tickoo S, Trpkov K, Zhou M, Delahunt B, Comperat E. [Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations]. *Ann Pathol*. 2014 Dec;34(6):448-61. doi: 10.1016/j.annpat.2014.10.003. Epub 2014 Nov 18. French. PubMed PMID: 25499860.
192. Tian W, Guner G, Miyamoto H, Cimino-Mathews A, Gonzalez-Roibon N, Argani P, Li X, Sharma R, Subhawong AP, Rezaei K, Bivalacqua TJ, Epstein JI, Bishop JA, **Netto GJ**. Utility of uroplakin II expression as a marker of urothelial carcinoma. *Hum Pathol*. 2015 Jan;46(1):58-64. doi: 10.1016/j.humpath.2014.09.007. Epub 2014 Oct 2. PubMed PMID: 25449628.
193. McNeil BK, Sorbellini M, Grubb RL 3rd, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, **Netto GJ**, Shih J, Linehan WM, Pinto PA, Bottaro DP. Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder. *J Transl Med*. 2014 Oct 21;12:199. doi: 10.1186/1479-5876-12-199. PubMed PMID: 25335552; PubMed Central PMCID: PMC4283116.
194. Argani P, Lewin JR, Edmonds P, **Netto GJ**, Prieto-Granada C, Zhang L, Jungbluth AA, Antonescu CR. Primary Renal Sclerosing Epithelioid Fibrosarcoma: Report of 2 Cases With EWSR1-CREB3L1 Gene Fusion. *Am J Surg Pathol*. 2015 Mar;39(3):365-373. PubMed PMID: 25353281.
195. Hsu I, Yeh CR, Slavin S, Miyamoto H, **Netto GJ**, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. *Oncotarget*. 2014 Sep 15;5(17):7917-35. PubMed PMID: 25277204; PubMed Central PMCID: PMC4202170.
196. Banet N, Gown AM, Shih IeM, Kay Li Q, Roden RB, Nucci MR, Cheng L, Przybycin CG, Nasser-Nik N, Wu LS, **Netto GJ**, Ronnett BM, Vang R. GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. *Am J Surg Pathol*. 2015 Jan;39(1):101-8. PubMed PMID: 25188865; PubMed Central PMCID: PMC4268033.
197. Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Ellis C, Driscoll T, Schoenberg MP, Bivalacqua TJ, Shih IeM, **Netto GJ**. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. *Hum Pathol*. 2014 Nov;45(11):2233-9. doi: 10.1016/j.humpath.2014.07.003. Epub 2014 Jul 23. PubMed PMID: 25175170.
198. Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, Lin O, McKenney JK, Montironi R, Paner GP, Al-Ahmadie HA, Algaba F, Ali S, Alvarado-Cabrero I, Bubendorf L, Cheng L, Cheville JC, Kristiansen G, Cote RJ, Delahunt B, Eble JN, Genega EM, Gulmann C,

- Hartmann A, Langner C, Lopez-Beltran A, Magi-Galluzzi C, Merce J, **Netto GJ**, Oliva E, Rao P, Ro JY, Srigley JR, Tickoo SK, Tsuzuki T, Umar SA, Van der Kwast T, Young RH, Soloway MS. Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. *Mod Pathol*. 2014 Nov 21. doi: 10.1038/modpathol.2014.158. [Epub ahead of print]. PubMed PMID: 25412849.
199. Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu JJ, Kates M, Hoque M, Berman D, Hahn NM, Eisenberger M, **Netto GJ**, Schoenberg MP, Bivalacqua TJ. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. *Urol Oncol*. 2015 Mar 23. pii: S1078-1439(15)00072-1. doi:10.1016/j.urolonc.2015.02.011. [Epub ahead of print] PubMed PMID: 25814145.
 200. Faraj SF, Munari E, Guner G, Taube J, Anders R, Hicks J, Meeker A, Schoenberg M, Bivalacqua T, Drake C, **Netto GJ**. Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma. *Urology*. 2015 Mar;85(3):703.e1-6. doi: 10.1016/j.urology.2014.10.020. PubMed PMID: 25733301.
 201. Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Cubilla AL, Shih IeM, **Netto GJ**. Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. *Hum Pathol*. 2015 May;46(5):761-6. doi: 10.1016/j.humpath.2015.01.018. Epub 2015 Feb 12. PubMed PMID: 25776029.
 202. Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, **Netto GJ**, Lodge MA, Mease RC, Pomper MG, Cho SY. 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. *J Nucl Med*. 2015 Jul;56(7):1003-10. doi: 10.2967/jnumed.115.154336. Epub 2015 Jun 11. PubMed PMID: 26069305
 203. Ross AE, Johnson MH, Yousefi K, Davicioni E, **Netto GJ**, Marchionni L, Fedor HL, Glavaris S, Choeung V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. *Eur Urol*. 2015 Jun 6. pii:S0302-2838(15)00444-3. doi: 10.1016/j.eururo.2015.05.042. [Epub ahead of print] PubMed PMID: 26058959.
 204. Smith NE, Epstein JI, Parwani AV, **Netto GJ**, Illei PB, Powell K, Allaf ME, Argani P. Smooth muscle and adenoma-like renal tumor: a previously unreported variant of mixed epithelial stromal tumor or a distinctive renal neoplasm? *Hum Pathol*. 2015 Jun;46(6):894-905. doi: 10.1016/j.humpath.2015.02.003. Epub 2015 Feb 19. PubMed PMID: 25911262.
 205. Hurley PJ, Hughes RM, Simons B, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kinura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, **Netto GJ**, Yegnasubramanian S, An S, Schaeffer E. Androgen Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. *Cancer Res*. 2015 Aug 20. pii: canres.0024.2015. [Epub ahead of print] PubMed PMID: 26294211.
 206. Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks JL, Gupta N, Epstein JI, **Netto GJ**, Isaacs WB, Luo J, Mehra R, Vessella RL, Karnes RJ, Schaeffer E, Davicioni E, De Marzo AM, Lotan TL. Cyclin D1 Loss Distinguishes Prostatic Small Cell Carcinoma from Most Prostatic Adenocarcinomas. *Clin Cancer Res*. 2015 Aug 5. pii: clincanres.0744.2015. [Epub ahead of print] PubMed PMID: 26246306.
 207. Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, Schoenberg M, Hahn N, Hoque M, Berman D, Bivalacqua TJ, **Netto GJ**. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.

- PLoS One. 2015 Jul 31;10(7):e0131245. doi: 10.1371/journal.pone.0131245. eCollection 2015. PubMed PMID: 26230923; PubMed Central PMCID: PMC4521868.
208. Morais CL, Herawi M, Toubaji A, Albadine R, Hicks J, **Netto GJ**, De Marzo AM, Epstein JI, Lotan TL. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. *Prostate*. 2015 Oct;75(14):1610-9. doi: 10.1002/pros.23042. Epub 2015 Jul 14. PubMed PMID: 26178158; PubMed Central PMCID: PMC4537350.
 209. Ozluk Y, Taheri D, Matoso A, Sanli O, Berker NK, Yakirevich E, Balasubramanian S, Ross JS, Ali SM, **Netto GJ**. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. *Hum Pathol*. 2015 Sep 5. [Epub ahead of print] PubMed PMID: 26476567.
 210. Ball MW, Gorin MA, Harris KT, Curtiss KM, **Netto GJ**, Pavlovich CP, Pierorazio PM, Allaf ME. Extent of Renal Vein Invasion Influences Prognosis in Patients with Renal Cell Carcinoma. *BJU Int*. 2015 Oct 11. doi: 10.1111/bju.13349. [Epub ahead of print] PubMed PMID: 26456548.
 211. Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, **Netto GJ**, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An S, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer E. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer. *Clin Cancer Res*. 2015 Oct 7. pii: clincanres.0256.2015. [Epub ahead of print] PubMed PMID: 26446945.
 212. Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, **Netto GJ**, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. *Oncotarget*. 2015 Sep 8. [Epub ahead of print] PubMed PMID: 26384299.
 213. Kawahara T, Shareef HK, Aljarah AK, Ide H, Li Y, Kashiwagi E, **Netto GJ**, Zheng Y, Miyamoto H. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. *Oncotarget*. 2015 Oct 6;6(30):29860-76. doi: 10.18632/oncotarget.5007. PubMed PMID: 26342199.
 214. Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, **Netto GJ**, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Kobel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta analysis. *Oncotarget*. 2015;6(36):39088-97. Epub 2015/09/19. doi: 10.18632/oncotarget.5142. PubMed PMID: 26384299; PubMed Central PMCID: PMC4770758.
 215. Ozluk Y, Taheri D, Matoso A, Sanli O, Berker NK, Yakirevich E, Balasubramanian S, Ross JS, Ali SM, **Netto GJ**. Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. *Human pathology*. 2015;46(12):1951-5. Epub 2015/10/20. doi:10.1016/j.humpath.2015.07.027. PubMed PMID: 26476567.
 216. Argani P, Lee J, **Netto GJ**, Zheng G, Tseh-Lin M, Park BH. Frequent BRAF V600E Mutations in Metanephric Stromal Tumor. *The American journal of surgical pathology*. 2016;40(5):719-22. Epub 2016/01/23. doi: 10.1097/pas.0000000000000603. PubMed PMID: 26796506.
 217. Argani P, Reuter VE, Zhang L, Sung YS, Ning Y, Epstein JI, **Netto GJ**, Antonescu CR. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable

Melanocytic Marker Expression and Morphologic Heterogeneity. *The American journal surgical pathology*. 2016;40(11):1484-95. Epub 2016/10/19. doi: 10.1097/pas.0000000000000720. PubMed PMID: 27565001; PubMed Central PMCID: PMC5069163.

218. Argani P, Zhong M, Reuter VE, Fallon JT, Epstein JI, **Netto GJ**, Antonescu CR. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. *The American journal of surgical pathology*. 2016;40(6):723-37. Epub 2016/03/15. doi: 10.1097/pas.0000000000000631. PubMed PMID: 26975036; PubMed Central PMCID: PMC4864095.
219. Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, **Netto GJ**, Xu H, Pritchard TS, Fan J, Cheadle C, Cope L, Drake CG, Pardoll DM, Taube JM, Topalian SL. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. *Cancer immunology research*. 2016;4(9):726-33. Epub 2016/08/06. doi: 10.1158/2326-6066.cir-16-0072. PubMed PMID: 27491898.
220. Ball MW, Bezerra SM, Chaux A, Faraj SF, Gonzalez-Roibon N, Munari E, Sharma R, Bivalacqua TJ, **Netto GJ**, Burnett AL. Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression. *Urology*. 2016;92:51-6. Epub 2016/02/26. doi: 10.1016/j.urology.2016.02.006. PubMed PMID: 26905033; PubMed Central PMCID: PMC4874837.
221. Ball MW, Gorin MA, Harris KT, Curtiss KM, **Netto GJ**, Pavlovich CP, Pierorazio PM, Allaf ME. Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma. *BJU international*. 2016;118(1):112-7. Epub 2015/10/13. doi: 10.1111/bju.13349. PubMed PMID: 26456548; PubMed Central PMCID: PMC4828325.
222. Brant A, Kates M, Chappidi MR, Patel HD, Sopko NA, **Netto GJ**, Baras AS, Hahn NM, Pierorazio PM, Bivalacqua TJ. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? *Urologic oncology*. 2016. Epub 2016/09/19. doi: 10.1016/j.urolonc.2016.08.005. PubMed PMID: 27639777.
223. Chalfin HJ, Liu JJ, Gandhi N, Feng Z, Johnson D, **Netto GJ**, Drake CG, Hahn NM, Schoenberg MP, Trock BJ, Scott AV, Frank SM, Bivalacqua TJ. Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy. *Annals of surgical oncology*. 2016;23(8):2715-22. Epub 2016/03/26. doi: 10.1245/s10434-016-5193-4. PubMed PMID: 27012987.
224. Chen G, Yang Z, Eshleman JR, **Netto GJ**, Lin MT. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. *BioMed research international*. 2016;2016:9850690. Epub 2016/10/05. doi: 10.1155/2016/9850690. PubMed PMID: 27699178.
225. Cocks M, Taheri D, Ball MW, Bezerra SM, Del Carmen Rodriguez M, Ricardo BF, Bivalacqua TJ, Sharma RB, Meeker A, Chaux A, Burnett AL, **Netto GJ**. Immune checkpoint status in penile squamous cell carcinoma: A North American Cohort. *Human pathology*. 2016. Epub 2016/09/25. doi: 10.1016/j.humpath.2016.09.003. PubMed PMID: 27663086.
226. Cowan M, Springer S, Nguyen D, Taheri D, Guner G, Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Cunha I, Fujita K, Ertoy D, Bivalacqua TJ, Kinzler K, Vogelstein B, **Netto GJ**, Papadopoulos N. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2016;29(5):511-5. Epub 2016/03/12. doi: 10.1038/modpathol.2016.53. PubMed PMID: 26965579.

227. Cowan ML, Springer S, Nguyen D, Taheri D, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, Del Carmen Rodriguez Pena M, VandenBussche CJ, Olson MT, Cunha I, Fujita K, Ertoy D, Kinzler K, Bivalacqua T, Papadopoulos N, Vogelstein B, **Netto GJ**. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. *Human pathology*. 2016;53:8-13. Epub 2016/03/17. doi: 10.1016/j.humpath.2016.02.009. PubMed PMID: 26980028.
228. Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, **Netto GJ**. Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. *PloS one*. 2016;11(1):e0146189. Epub 2016/01/06. doi: 10.1371/journal.pone.0146189. PubMed PMID: 26731672; PubMed Central PMCID: PMC4712132.
229. Guner G, Bishop JA, Bezerra SM, Taheri D, Zahavi DJ, Mendoza Rodriguez MA, Sharma R, Epstein JI, **Netto GJ**. The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. *Human pathology*. 2016;54:184-8. Epub 2016/04/14. doi: 10.1016/j.humpath.2016.03.011. PubMed PMID: 27068523.
230. Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, Benzon B, Faraj SF, **Netto GJ**, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing C, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An SS, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2016;22(2):448-58. Epub 2015/10/09. doi: 10.1158/1078-0432.ccr-15-0256. PubMed PMID: 26446945; PubMed Central PMCID: PMC4715968.
231. Kashiwagi E, Fujita K, Yamaguchi S, Fushimi H, Ide H, Inoue S, Mizushima T, Reis LO, Sharma R, **Netto GJ**, Nonomura N, Miyamoto H. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. *Cancer biology & therapy*. 2016;1-9. Epub 2016/10/22. doi: 10.1080/15384047.2016.1235667. PubMed PMID: 27635763.
232. Kawahara T, Inoue S, Ide H, Kashiwagi E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, **Netto GJ**, Ishiguro H, Miyamoto H. ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. *Oncotarget*. 2016. Epub 2016/07/23. doi: 10.18632/oncotarget.10679. PubMed PMID: 27447553.
233. Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Comperat E, Delahunt B, Egevad L, Evans AJ, Hansel DE, Humphrey PA, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, **Netto GJ**, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, van Leenders GJ. Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. *Histopathology*. 2016;69(3):441-9. Epub 2016/03/31. doi: 10.1111/his.12976. PubMed PMID: 27028587.
234. Munari E, Chaux A, Vaghasia AM, Taheri D, Karram S, Bezerra SM, Gonzalez Roibon N, Nelson WG, Yegnasubramanian S, **Netto GJ**, Haffner MC. Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. *PloS one*. 2016;11(1):e0146302. Epub 2016/01/20. doi: 10.1371/journal.pone.0146302. PubMed PMID: 26785262; PubMed Central PMCID: PMC4718593.
235. **Netto GJ**. Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. *Lancet (London, England)*. 2016;387(10031):1881-2. Epub 2016/03/10. doi: 10.1016/s0140-6736(16)00654-1. PubMed PMID: 26952549.

236. Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Ricardo BF, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, **Netto GJ**. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. *Virchows Archiv : an international journal of pathology*. 2016;469(4):427-34. Epub 2016/08/16. doi: 10.1007/s00428-016-2001-2. PubMed PMID: 27520411.
237. Park JC, Gandhi NM, Carducci MA, Eisenberger MA, Baras AS, **Netto GJ**, Liu JJ, Drake CG, Schoenberg MP, Bivalacqua TJ, Hahn NM. A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer. *The Journal of urology*. 2016;195(4p1):880-5. Epub 2015/11/26. doi: 10.1016/j.juro.2015.11.024. PubMed PMID: 26598426.
238. Reis LO, Taheri D, Chaux A, Guner G, Mendoza Rodriguez MA, Bivalacqua TJ, Schoenberg MP, Epstein JI, **Netto GJ**. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. *Human pathology*. 2016;47(1):20-5. Epub 2015/11/02. doi: 10.1016/j.humpath.2015.09.007. PubMed PMID: 26520419.
239. Shekhani MT, Barber JR, Bezerra SM, Heaphy CM, Gonzalez Roibon ND, Taheri D, Reis LO, Guner G, Joshi CE, **Netto GJ**, Meeker AK. High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors. *Human pathology*. 2016;54:106-12. Epub 2016/04/18. doi: 10.1016/j.humpath.2016.03.015. PubMed PMID: 27085557.
240. Taheri D, Zahavi DJ, Del Carmen Rodriguez M, Meliti A, Rezaee N, Yonescu R, Ricardo BF, Dolatkah S, Ning Y, Bishop JA, **Netto GJ**, Sharma R. For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody. *Virchows Archiv : an international journal of pathology*. 2016;469(3):345-50. Epub 2016/06/09. doi: 10.1007/s00428-016-1969-y. PubMed PMID: 27271275.
241. Zheng G, Lin MT, Lokhandwala PM, Beierl K, **Netto GJ**, Gocke CD, Eshleman JR, McCarthy E, Illei PB. Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing. *Cancer*. 2016;124(10):744-53. Epub 2016/06/11. doi: 10.1002/cncy.21743. PubMed PMID: 27286239.
242. Guedes L, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, **Netto GJ**, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL. Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer. *Clin Cancer Res*. 2017 Apr 26. pii: clincanres.0257.2017. doi:10.1158/1078-0432.CCR-17-0257. [Epub ahead of print] PubMed PMID: 28446506.
243. Inoue S, Mizushima T, Fujita K, Meliti A, Ide H, Yamaguchi S, Fushimi H, **Netto GJ**, Nonomura N, Miyamoto H. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker as well as a prognosticator. *Hum Pathol*. 2017 Apr 17. pii: S0046-8177(17)30110-7. doi:10.1016/j.humpath.2017.04.003. [Epub ahead of print] PubMed PMID: 28428106.
244. Marchionni L, Hayashi M, Guida E, Ooki A, Munari E, Jabboure FJ, Dinalankara W, Raza A, **Netto GJ**, Hoque MO, Argani P. MicroRNA expression profiling of Xp11 renal cell carcinoma. *Hum Pathol*. 2017 Apr 11. pii: S0046-8177(17)30093-X. doi:10.1016/j.humpath.2017.03.011. [Epub ahead of print] PubMed PMID: 28411178.
245. Faraj SF, Gonzalez-Roibon N, Munari E, Sharma R, Burnett AL, Cubilla AL, **Netto GJ**, Chaux A. Strong association of insulin-like growth factor 1 receptor expression with histologic grade, subtype, and HPV status in penile squamous cell carcinomas: a tissue microarray study of 112

cases. *Virchows Arch.* 2017 Mar 27. doi: 10.1007/s00428-017-2110-6. [Epub ahead of print] PubMed PMID: 28349238.

246. Torres A, Alshalalfa M, Tomlins SA, Erho N, Gibb EA, Chelliserry J, Lim L, Lam LLC, Faraj SF, Bezerra SM, Davicioni E, Yousefi K, Ross AE, **Netto GJ**, Schaeffer EM, Lotan TL. Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. *J Mol Diagn.* 2017 May;19(3):475-484. doi: 10.1016/j.jmoldx.2017.01.007. Epub 2017 Mar 21. PubMed PMID: 28341589.
247. Chappidi MR, Kates M, Brant A, Baras AS, **Netto GJ**, Pierorazio PM, Hahn NM, Bivalacqua TJ. Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. *Urology.* 2017 Apr;102:148-158. doi: 10.1016/j.urology.2016.10.064. Epub 2017 Jan 16. PubMed PMID: 28104421; PubMed Central PMCID: PMC5376379.
248. Ball MW, Schwen ZR, Ko JS, Meyer A, **Netto GJ**, Burnett AL, Bivalacqua TJ. Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer. *Investig Clin Urol.* 2017 Jan;58(1):20-26. doi:10.4111/icu.2017.58.1.20. Epub 2017 Jan 4. PubMed PMID: 28097264; PubMed Central PMCID: PMC5240287.
249. Hahn NM, Bivalacqua TJ, Ross AE, **Netto GJ**, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrl R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. *Clin Cancer Res.* 2016 Dec 8. doi:10.1158/1078-0432.CCR-16-2267. [Epub ahead of print] PubMed PMID: 27932416.
250. Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, **Netto GJ**, Partin AW, Trock BJ, Davicioni E, Schaeffer EM. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. *J Urol.* 2016 Nov;196(5):1436-1444. doi:10.1016/j.juro.2016.05.092. Epub 2016 May 27. PubMed PMID: 27238617.
251. Morbeck D, Tregnago AC, **Netto GJB**, Sacomani C, Peresi PM, Osório CT, Schutz L, Bezerra SM, de Brot L, Cunha IW. GATA3 expression in primary vulvar Paget disease: a potential pitfall leading to misdiagnosis of pagetoid urothelial intraepithelial neoplasia. *Histopathology.* 2017 Feb;70(3):435-441. doi: 10.1111/his.13086. Epub 2016 Nov 21. Erratum in: *Histopathology.* 2017 May;70(6):1016. PubMed PMID: 27633145.
252. Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, **Netto GJ**, Bivalacqua TJ. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. *Oncoimmunology.* 2016 Feb 18;5(5):e1134412. doi:10.1080/2162402X.2015.1134412. eCollection 2016 May. PubMed Central PMCID: PMC4910705.
253. Munari E, Chaux A, Vaghasia AM, Taheri D, Karram S, Bezerra SM, Gonzalez Roibon N, Nelson WG, Yegnasubramanian S, **Netto GJ**, Haffner MC. Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies. *PLoS One.* 2016 Jan 19;11(1):e0146302. doi: 10.1371/journal.pone.0146302. eCollection 2016. PubMed PMID: 26785262; PubMed Central PMCID: PMC4718593.
254. Argani P, Lee J, **Netto GJ**, Zheng G, Tseh-Lin M, Park BH. Frequent BRAF V600E Mutations in Metanephric Stromal Tumor. *Am J Surg Pathol.* 2016 May;40(5):719-22. doi: 10.1097/PAS.0000000000000603. PubMed PMID: 26796506.

255. Cowan M, Springer S, Nguyen D, Taheri D, Guner G, Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Cunha I, Fujita K, Ertoy D, Bivalacqua TJ, Kinzler K, Vogelstein B, **Netto GJ**, Papadopoulos N. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. *Mod Pathol*. 2016 May;29(5):511-5. doi: 10.1038/modpathol.2016.53. Epub 2016 Mar 11. PubMed PMID: 26965579; PubMed Central PMCID: PMC5564297.
256. Ball MW, Bezerra SM, Chaux A, Faraj SF, Gonzalez-Roibon N, Munari E, Sharma R, Bivalacqua TJ, **Netto GJ**, Burnett AL. Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated with Penile Cancer Progression. *Urology*. 2016 Jun;92:51-6. doi: 10.1016/j.urology.2016.02.006. Epub 2016 Feb 18. PubMed PMID: 26905033; PubMed Central PMCID: PMC4874837.
257. Zheng G, Tsai H, Tseng LH, Illei P, Gocke CD, Eshleman JR, **Netto GJ**, Lin MT. Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. *Am J Clin Pathol*. 2016 May;145(5):696-702. doi: 10.1093/ajcp/aqw043. PubMed PMID: 27247373.
258. Zheng G, Lin MT, Lokhandwala PM, Beierl K, **Netto GJ**, Gocke CD, Eshleman JR, McCarthy E, Illei PB. Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing. *Cancer*. 2016 Oct;124(10):744-753. doi: 10.1002/cncy.21743. Epub 2016 Jun 10. PubMed PMID: 27286239.
259. Torres A, Alshalalfa M, Tomlins SA, Erho N, Gibb EA, Chelliserry J, Lim L, Lam LLC, Faraj SF, Bezerra SM, Davicioni E, Yousefi K, Ross AE, **Netto GJ**, Schaeffer EM, Lotan TL. Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. *J Mol Diagn*. 2017 May;19(3):475-484. doi: 10.1016/j.jmoldx.2017.01.007. Epub 2017 Mar 21. PubMed PMID: 28341589; PubMed Central PMCID: PMC5417038.
260. Taheri D, Zahavi DJ, Del Carmen Rodriguez M, Meliti A, Rezaee N, Yonescu R, Ricardo BF, Dolatkah S, Ning Y, Bishop JA, **Netto GJ**, Sharma R. For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody. *Virchows Arch*. 2016 Sep;469(3):345-50. doi:10.1007/s00428-016-1969-y. Epub 2016 Jun 6. PubMed PMID: 27271275.
261. Shekhani MT, Barber JR, Bezerra SM, Heaphy CM, Gonzalez Roibon ND, Taheri D, Reis LO, Guner G, Joshu CE, **Netto GJ**, Meeker AK. High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors. *Hum Pathol*. 2016 Aug;54:106-12. doi:10.1016/j.humpath.2016.03.015. Epub 2016 Apr 13. PubMed PMID: 27085557.
262. Rodriguez Pena MDC, Tregnago AC, Eich ML, Springer S, Wang Y, Taheri D, Ertoy D, Fujita K, Bezerra SM, Cunha IW, Raspollini MR, Yu L, Bivalacqua TJ, Papadopoulos N, Kinzler KW, Vogelstein B, **Netto GJ**. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. *Virchows Arch*. 2017 Jun 8. doi:10.1007/s00428-017-2164-5. [Epub ahead of print] PubMed PMID: 28597078.
263. Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Ricardo BF, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, **Netto GJ**. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. *Virchows Arch*. 2016 Oct;469(4):427-34. doi: 10.1007/s00428-016-2001-2. Epub 2016 Aug 12. PubMed PMID: 27520411; PubMed Central PMCID: PMC5561427.
264. Morbeck D, Tregnago AC, **Netto GJB**, Sacomani C, Peresi PM, Osório CT, Schutz L, Bezerra SM, de Brot L, Cunha IW. GATA3 expression in primary vulvar Paget disease: a potential

- pitfall leading to misdiagnosis of pagetoid urothelial intraepithelial neoplasia. *Histopathology*. 2017 Feb;70(3):435-441. doi:10.1111/his.13086. Epub 2016 Nov 21. Erratum in: *Histopathology*. 2017 May;70(6):1016. PubMed PMID: 27633145.
265. Marchionni L, **Netto GJ**, Hoque M, Argani P. MicroRNAs, promising biomarkers in the diagnosis of Xp11 translocation RCC-reply. *Hum Pathol*. 2017 Aug 12. pii: S0046-8177(17)30270-8. doi: 10.1016/j.humpath.2017.06.021. [Epub ahead of print] PubMed PMID: 28811253.
 266. Marchionni L, Hayashi M, Guida E, Ooki A, Munari E, Jabboue FJ, Dinalankara W, Raza A, **Netto GJ**, Hoque MO, Argani P. MicroRNA expression profiling of Xp11 renal cell carcinoma. *Hum Pathol*. 2017 Apr 11. pii: S0046-8177(17)30093-X. doi:10.1016/j.humpath.2017.03.011. [Epub ahead of print] PubMed PMID: 28411178.
 267. Li Y, Reuter VE, Matoso A, **Netto GJ**, Epstein JI, Argani P. Re-evaluation of 33 "Unclassified" Eosinophilic Renal Cell Carcinomas in Young Patients. *Histopathology*. 2017 Sep 12. doi: 10.1111/his.13395. [Epub ahead of print] PubMed PMID: 28898443.
 268. Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Comp rat E, Delahunt B, Egevad L, Evans AJ, Hansel DE, Humphrey PA, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, **Netto GJ**, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, van Leenders GJ. Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. *Histopathology*. 2016 Sep;69(3):441-9. doi: 10.1111/his.12976. Epub 2016 May 24. PubMed PMID: 27028587.
 269. Kawahara T, Inoue S, Ide H, Kashiwagi E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, **Netto GJ**, Ishiguro H, Miyamoto H. ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. *Oncotarget*. 2016 Aug 16;7(33):53599-53610. doi: 10.18632/oncotarget.10679. PubMed PMID: 27447553; PubMed Central PMCID: PMC5288208.
 270. Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, **Netto GJ**, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ. Intravesical BCG Induces CD4(+) T-Cell Expansion in an Immune Competent Model of Bladder Cancer. *Cancer Immunol Res*. 2017 Jul;5(7):594-603. doi: 10.1158/2326-6066.CIR-16-0267. Epub 2017 Jun 6. PubMed PMID: 28588015; PubMed Central PMCID: PMC5536898.
 271. Kashiwagi E, Fujita K, Yamaguchi S, Fushimi H, Ide H, Inoue S, Mizushima T, Reis LO, Sharma R, **Netto GJ**, Nonomura N, Miyamoto H. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. *Cancer Biol Ther*. 2016 Nov;17(11):1188-1196. Epub 2016 Sep 16. PubMed PMID: 27635763; PubMed Central PMCID: PMC5137486.
 272. Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, **Netto GJ**, Partin AW, Trock BJ, Davicioni E, Schaeffer EM. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. *J Urol*. 2016 Nov;196(5):1436-1444. doi: 10.1016/j.juro.2016.05.092. Epub 2016 May 27. PubMed PMID: 27238617.
 273. Inoue S, Mizushima T, Fujita K, Meliti A, Ide H, Yamaguchi S, Fushimi H, **Netto GJ**, Nonomura N, Miyamoto H. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. *Hum Pathol*. 2017 Jun;64:83-90. doi: 10.1016/j.humpath.2017.04.003. Epub 2017 Apr 17. PubMed PMID: 28428106.
 274. Hahn NM, Bivalacqua TJ, Ross AE, **Netto GJ**, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB,

- Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. *Clin Cancer Res*. 2017 Jun 15;23(12):3003-3011. doi:10.1158/1078-0432.CCR-16-2267. Epub 2016 Dec 8. PubMed PMID: 27932416; PubMed Central PMCID: PMC5462889.
275. Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, **Netto GJ**, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S. AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. *Nat Commun*. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8. PubMed PMID: 28747635; PubMed Central PMCID:PMC5529512.
276. Guner G, Bishop JA, Bezerra SM, Taheri D, Zahavi DJ, Mendoza Rodriguez MA, Sharma R, Epstein JI, **Netto GJ**. The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms. *Hum Pathol*. 2016 Aug;54:184-8. doi: 10.1016/j.humpath.2016.03.011. Epub 2016 Apr 8. PubMed PMID: 27068523.
277. Cowan ML, Springer S, Nguyen D, Taheri D, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, Del Carmen Rodriguez Pena M, VandenBussche CJ, Olson MT, Cunha I, Fujita K, Ertoy D, Kinzler K, Bivalacqua T, Papadopoulos N, Vogelstein B, **Netto GJ**. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. *Hum Pathol*. 2016 Jul;53:8-13. doi:10.1016/j.humpath.2016.02.009. Epub 2016 Mar 10. PubMed PMID: 26980028; PubMed Central PMCID: PMC5561423.
278. Cocks M, Taheri D, Ball MW, Bezerra SM, Del Carmen Rodriguez M, Ricardo BF, Bivalacqua TJ, Sharma RB, Meeker A, Chaux A, Burnett AL, **Netto GJ**. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. *Hum Pathol*. 2017 Jan;59:55-61. doi:10.1016/j.humpath.2016.09.003. Epub 2016 Sep 20. PubMed PMID: 27663086.
279. Chen G, Yang Z, Eshleman JR, **Netto GJ**, Lin MT. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. *Biomed Res Int*. 2016;2016:9850690. Epub 2016 Sep 6. Review. PubMed PMID: 27699178; PubMed Central PMCID: PMC5028795.
280. Ball MW, Gorin MA, Guner G, Pierorazio PM, **Netto GJ**, Paller CJ, Hammers HJ, Diaz LA, Allaf ME. Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. *Clin Genitourin Cancer*. 2016 Oct;14(5):e515-e520. doi: 10.1016/j.clgc.2016.03.019. Epub 2016 Mar 24. PubMed PMID: 27150639; PubMed Central PMCID: PMC5035558.
281. Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, **Netto GJ**, Xu H, Pritchard TS, Fan J, Cheadle C, Cope L, Drake CG, Pardoll DM, Taube JM, Topalian SL. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. *Cancer Immunol Res*. 2016 Sep 2;4(9):726-33. doi: 10.1158/2326-6066.CIR-16-0072. Epub 2016 Aug 4. PubMed PMID: 27491898; PubMed Central PMCID: PMC5584610.
282. Argani P, Zhong M, Reuter VE, Fallon JT, Epstein JI, **Netto GJ**, Antonescu CR. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. *Am J Surg Pathol*. 2016 Jun;40(6):723-37. doi:10.1097/PAS.0000000000000631. PubMed PMID: 26975036; PubMed Central PMCID:PMC4864095.
283. Guedes LB, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, **Netto GJ**, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL. Analytic,

- Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. *Clin Cancer Res.* 2017 Aug
284. Faraj SF, Gonzalez-Roibon N, Munari E, Sharma R, Burnett AL, Cubilla AL, **Netto GJ**, Chaux A. Strong association of insulin-like growth factor 1 receptor expression with histologic grade, subtype, and HPV status in penile squamous cell carcinomas: a tissue microarray study of 112 cases. *Virchows Arch.* 2017 Jun;470(6):695-701. doi: 10.1007/s00428-017-2110-6. Epub 2017 Mar 27. PubMed PMID: 28349238.
 285. Chappidi MR, Kates M, Brant A, Baras AS, **Netto GJ**, Pierorazio PM, Hahn NM, Bivalacqua TJ. Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. *Urology.* 2017 Apr;102:148-158. doi: 10.1016/j.urology.2016.10.064. Epub 2017 Jan 16. PubMed PMID: 28104421; PubMed Central PMCID: PMC5376379.
 286. Chalfin HJ, Liu JJ, Gandhi N, Feng Z, Johnson D, **Netto GJ**, Drake CG, Hahn NM, Schoenberg MP, Trock BJ, Scott AV, Frank SM, Bivalacqua TJ. Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy. *Ann Surg Oncol.* 2016 Aug;23(8):2715-22. doi:10.1245/s10434-016-5193-4. Epub 2016 Mar 24. PubMed PMID: 27012987.
 287. Brant A, Kates M, Chappidi MR, Patel HD, Sopko NA, **Netto GJ**, Baras AS, Hahn NM, Pierorazio PM, Bivalacqua TJ. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? *Urol Oncol.* 2017 Jan;35(1):34.e17-34.e25. doi: 10.1016/j.urolonc.2016.08.005. Epub 2016 Sep 14. PubMed PMID: 27639777.
 288. Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, **Netto GJ**, Bivalacqua TJ. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. *Oncoimmunology.* 2016 Feb 18;5(5):e1134412. doi:10.1080/2162402X.2015.1134412. eCollection 2016 May. PubMed PMID: 27467953; PubMed Central PMCID: PMC4910705.
 289. Ball MW, Schwen ZR, Ko JS, Meyer A, **Netto GJ**, Burnett AL, Bivalacqua TJ. Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer. *Investig Clin Urol.* 2017 Jan;58(1):20-26. doi: 10.4111/icu.2017.58.1.20. Epub 2017 Jan 4. PubMed PMID: 28097264; PubMed Central PMCID: PMC5240287.
 290. Argani P, Reuter VE, Zhang L, Sung YS, Ning Y, Epstein JI, **Netto GJ**, Antonescu CR. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity. *Am J Surg Pathol.* 2016 Nov;40(11):1484-1495. PubMed PMID: 27565001; PubMed Central PMCID: PMC5069163. 15;23(16):4693-4703. doi: 10.1158/1078-0432.CCR-17-0257. Epub 2017 Apr 26. PubMed PMID: 28446506; PubMed Central PMCID: PMC5559307.
 291. Silvers CR, Miyamoto H, Messing EM, **Netto GJ**, Lee YF. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. *Oncotarget.* 2017 Aug 8;8(53):91199-91208. doi: 10.18632/oncotarget.20043. eCollection 2017 Oct 31. PubMed PMID: 29207636; PubMed Central PMCID: PMC5710916
 292. Ooki A, Del Carmen Rodriguez Pena M, Marchionni L, Dinalankara W, Begum A, Hahn NM, VandenBussche CJ, Rasheed ZA, Mao S, **Netto GJ**, Sidransky D, Hoque MO. YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells. *Cancer Res.* 2018 Jan 1;78(1):168-181. doi: 10.1158/0008-5472.CAN-17-0836. Epub 2017 Nov PubMed PMID: 29180467; PubMed Central PMCID: PMC5754245

293. Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, **Netto GJ**, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G. PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. *Oncotarget*. 2017 Oct 4;8(52):90123-90131. doi: 10.18632/oncotarget.21485. eCollection 2017 Oct 27. PubMed PMID: 29163815; PubMed Central PMCID: PMC5685736.
294. Kashiwagi E, Inoue S, Mizushima T, Chen J, Ide H, Kawahara T, Reis LO, Baras AS, **Netto GJ**, Miyamoto H. Prostaglandin receptors induce urothelial tumorigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. *Br J Cancer*. 2017 Nov 9. doi: 10.1038/bjc.2017.393. [Epub ahead of print] PubMed PMID: 29123257.
295. Lakis NS, Lombardo KA, Mangray S, **Netto GJ**, Salles D, Matoso A. INSL3 Expression in Leydig Cell Hyperplasia and Leydig Cell Tumors. *Appl Immunohistochem Mol Morphol*. 2017 Oct 27. doi: 10.1097/PAI.0000000000000567. [Epub ahead of print] PubMed PMID: 29084059.
296. Gevaert T, Montironi R, Lopez-Beltran A, Van Leenders G, Allory Y, De Ridder D, Claessens F, Kockx M, Akand M, Joniau S, **Netto G**, Libbrecht L. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. *Semin Cancer Biol*. 2017 Oct 12. pii: S1044-579X(17)30119-0. doi: 10.1016/j.semcancer.2017.10.004. [Epub ahead of print] Review. PubMed PMID: 29032188.
297. Chakravarthi BVSK, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, Jing X, Wang R, Mehra R, Asangani IA, Chinnaiyan AM, Manne U, Sonpavde G, **Netto GJ**, Gordetsky J, Varambally S. miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. *Mol Cancer Res*. 2017 Oct 12. doi: 10.1158/1541-7786.MCR-17-0230. [Epub ahead of print] PubMed PMID: 29025958.

Reviews

1. **Netto GJ**, Humphrey PA. Molecular biologic aspects of human prostatic carcinoma. *Am J Clin Pathol* 1994;102(S1):S57-S64.
2. **Netto GJ**, Saad R, Dysert PA. Diagnostic molecular pathology: current techniques and clinical applications. Part I. *Proc (Bayl Univ Med Cent)* 2003; 16:379-83.
3. **Netto G**, Saad R. Diagnostic molecular pathology. Part 2: Proteomics and clinical applications of molecular diagnostics in hematopathology. *Proc (Bayl Univ Med Cent)*, 2005; 18:7-12.
4. **Netto GJ**, Domiati-Saad R. Diagnostic molecular pathology: an increasingly indispensable tool for the practicing pathologist. *Arch Pathol Lab Med* 2006; 130(9):1339-4.
5. **Netto GJ** and Epstein JI: Theranostic and prognostic biomarkers: genomic applications in urologic malignancies. *Pathology* 2010 42(4):384-94.
6. Miyamoto H, Miller JS, Fajardo DA, Lee TK, **Netto GJ**, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. *Pathol Int* 2010; 60(1):1-8.
7. **Netto GJ**. Molecular diagnostics in urologic malignancies: a work in progress. *Arch Pathol Lab Med* 2011 May;135(5):610-21.
8. **Netto GJ**. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? *Nat Rev Urol* 2011; Dec 13;9(10):41-51.
9. **Netto GJ**, Cheng L. Emerging critical role of molecular testing in diagnostic genitourinary pathology. *Arch Pathol Lab Med*. 2012 Apr;136(4):372-90. Review. PubMed PMID: 22458900.

10. **Netto GJ.** Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "mirage"? *Adv Anat Pathol.* 2013. May; 20(3):175-203 Doi10.1097/PAP.0b013e3182863f80 Review. PubMed PMID:23574774.
11. **Netto GJ.** Molecular genetics and genomics progress in urothelial bladder cancer. *Semin Diagn Pathol.* 2013 Nov;30(4):313-20. doi:10.1053/j.semmp.2013.11.005. Epub 2013 Nov 11. Review. PubMed PMID: 24342287.
12. **Netto GJ.** Molecular Updates in Prostate Cancer. *Surgical pathology clinics.* 2015;8(4):561-80. Epub 2015/11/28. doi: 10.1016/j.path.2015.08.003. PubMed PMID: 26612215.
13. **Netto GJ, Tafe LJ.** Emerging Bladder Cancer Biomarkers and Targets of Therapy. *The Urologic clinics of North America.* 2016;43(1):63-76. Epub 2015/11/29. doi: 10.1016/j.ucl.2015.08.006. PubMed PMID: 26614029.
14. Voltaggio L, Cimino-Mathews A, Bishop JA, Argani P, Cuda JD, Epstein JI, Hruban RH, **Netto GJ**, Stoler MH, Taube JM, Vang R, Westra WH, Montgomery EA. Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. *CA: a cancer journal for clinicians.* 2016;66(5):408-36. Epub 2016/06/09. doi: 10.3322/caac.21350. PubMed PMID: 27270763.
15. Eich ML, Dyrskjøt L, **Netto GJ.** Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. *Virchows Arch.* 2017 Apr 21. doi:0.1007/s00428-017-2119-x. [Epub ahead of print] Review. PubMed PMID: 28429075.

BOOKS

1. *Prostate Biopsy Interpretation.* JI Epstein, **GJ Netto**, 4thed, Lippincott Williams & Wilkins, Philadelphia, 2007.
2. High Yield Genitourinary Pathology. M Zhou M, **GJ Netto**, JI Epstein, Editors; Elsevier, 2012
3. JI Epstein, **GJ Netto**: Differential Diagnosis in Surgical Pathology: Genitourinary System, Walters Kluwer Health, Baltimore, 2014
4. *Prostate Biopsy Interpretation.* JI Epstein, **GJ Netto**, 5thed, Lippincott Williams & Wilkins, Philadelphia, 2014.
5. Genomic Applications in Pathology. **GJ Netto** and I Schrijver, Editors. Springer , 2014

BOOK CHAPTERS

1. **Netto GJ.** Pathology of liver transplantation: grading and staging systems. In *Atlas of Liver Transplantation*, Molmenti & Klintmalm, eds., Elsevier Science, Chapter 37, 2002.
2. **Netto GJ.** Pathology of liver transplantation: recurrence of primary hepatic diseases in transplanted livers. In *Atlas of Liver Transplantation.* Molmenti & Klintmalm, eds, Elsevier Science, Chap 36, 2002.
3. **Netto GJ.** Pathology of liver transplantation: primary hepatic disease. In *Atlas of Liver Transplantation.* Molmenti & Klintmalm, eds, Elsevier Science, Chap35, 2002.
4. **Netto GJ.** Tumors of unknown primary origin: the role of immunohistochemistry and molecular diagnostics. In *American Society of Clinical Oncology 2002 Educational Book*, Perry MC, ed., Lippincott Williams & Wilkins, Baltimore, 2002;343-7.
5. Hansel DE, **Netto GJ**, Montgomery EA, Epstein JI. Mesenchymal tumors of the prostate. In *Surgical Pathology Clinics*, Vol 1, Issue 1, WB Saunders, 2008.
6. **Netto GJ**, Epstein JI. Benign Mimickers of prostate adenocarcinoma on needle biopsy and transurethral resection. In *Surgical Pathology Clinics*, Vol 1, Issue 1, WB Saunders, 2008.
7. **Netto GJ**, Epstein JI. Immunohistology and molecular diagnostics of the prostate, urinary bladder, kidney and testis neoplasms. In *Diagnostic Immunohistochemistry.* Dabbs D, ed, Churchill Livingstone Elsevier, 3rd ed, Chap 16; 2010.
8. Epstein JI and **Netto GJ**: The prostate and Seminal Vesicle. In *Sternberg's diagnostic surgical pathology.* Mills SE, ed. Lippincott Williams & Wilkins, 5thed, 2010: Chap 45: 1871-1913.
9. **GJ Netto** and Liang Cheng: Molecular Pathology of the Urinary Bladder. In *Molecular Surgical Pathology.* Liang Cheng and John N Eble eds Springer 2012: Chap11: 229-253

10. **GJ Netto:** Molecular Pathology of Bladder Cancer. In *Surgical Pathology Clinics Molecular Oncology*. Jennifer L Hunt and John R Goldblum eds. Vol 5, Issue 4, Elsevier 2012
11. **GJ Netto** and JI Epstein JI. Immunohistology of the Prostate. In Diagnostic Immunohistochemistry. Theranostic and Genomic Applications. David J Dabbs, ed, Elsevier, 4rd ed, Chap 16; 2014.
12. **GJ Netto** and JI Epstein JI. Immunohistology of the Bladder, Kidney and Testis. In Diagnostic Immunohistochemistry. Theranostic and Genomic Applications. David J Dabbs, ed, Elsevier, 4rd ed, Chap 17; 2014.
13. JI Epstein and **Netto GJ:** The prostate and Seminal Vesicle. In *Sternberg's diagnostic surgical pathology*. Mills SE, ed. Lippincott Williams & Wilkins, 6th ed, 2015
14. CS Foster and **GJ Netto:** Diseases of the Urinary Tract. In Silverberg's Principles and Practice of Surgical Pathology and Cytopathology, Wick, LiVolsi, Pfeifer, Stelow, & Wakely ed. Cambridge University Press 5th ed, 2015
15. **GJ Netto:** Molecular Pathology of Prostate Cancer, An Update. In *Surgical Pathology Clinics Molecular Oncology*. Michelle Hirsch and John R Goldblum eds. , 2015
16. **GJ Netto:** Urothelial Carcinoma Prognosis and Predictive factors: Genetic and Molecular Biomarkers. In **World Health Organization (WHO) Classification** of Tumours of the Urinary System and Male Genital Organs, 4th edition, Moch, Humphrey, Ulbright and Reuter. International Agency for Research on Cancer (IARC), Lyon cedex, France, 2016
17. **GJ Netto:** Prostate Carcinoma: Etiology and Genetic Susceptibility. In **World Health Organization (WHO) Classification** of Tumours of the Urinary System and Male Genital Organs, 4th edition, Moch, Humphrey, Ulbright and Reuter. International Agency for Research on Cancer (IARC), Lyon cedex, France, 2016

LETTERS AND OTHER PUBLICATIONS

1. Högenauer C, **Netto GJ**, Fordtran JS. Malabsorption due to cholecystokinin deficiency in a patient with Autoimmune Polyglandular Syndrome Type I. (Letter to the Editor) N Engl J Med 2001; 345:65-66.
2. **Netto GJ.** Branched DNA: another methodology for TMPRSS2-ERG fusion detection. Editorial Comment. Urology 2009;74(5):1161-2; author reply 1162.
3. **Netto GJ**, Lotan T, Albadine R, Latour M, Demarzo AM and Meeker A. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas; Response to letter to the editor. Mod Pathol 2009; 22:1399-1400.
4. **Netto GJ.** TMPRSS2-ERG fusion as a marker of prostatic lineage in small cell carcinoma. Comment on: Scheble et al. Histopathology 2010 Oct;57(4):633.
5. **Netto GJ.** Tumor volume threshold of insignificant prostate cancer-was Dr.Stamey right all along? J Urol 2011;185(1):10-11.
6. Bishop JA, Sharma R, **Netto GJ**, Illei PB. Thyroid transcription factor 1 expression in a case of renal collecting duct carcinoma-Reply. Hum Pathol. 2012 Jul;43(7):1154. PubMed PMID: 22703592.
7. Kaye DR, Walsh PC, **Netto GJ**, Gonzalez-Roibon N, Rodriguez R. A 66-Year-old Man with Prostate- specific Antigen Recurrence and Lung Mass after Radical Prostatectomy. Urology. 2012 Aug;80(2):247- PubMed PMID: 22673543.
8. **Netto GJ.** Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. Lancet. 2016 May 7;387(10031):1881-2. doi: 10.1016/S0140-6736(16)00654-1. Epub 2016 Mar 4. PubMed PMID: 26952549.
9. Bosman FT, **Netto GJ.** Preparing pathology for the molecular era. Virchows Arch. 2017 Aug;471(2):137-140. doi: 10.1007/s00428-017-2198-8. PubMed PMID: 28714037.

INVITED TALKS AND SEMINARS – INTERNATIONAL

- 1994 Prostatic Changes Following Androgen-Deprivation Therapy, Department of Urology, Montreal General Hospital, McGill University, Montreal, Canada
- 1994 "Apoptosis," Department of Pathology, Montreal General Hospital, McGill University, Montreal, Canada
- 1995 Prostatic Intraepithelial Neoplasia: A Clinically Significant Premalignant Lesion (Seminar). International Academy of Pathology, Arab Division, WHO Sponsored 7th Scientific Meeting, University of Damascus, Faculty of Medicine, Damascus, Syria
- 1995 Programmed Cell Death: Molecular Basis and Association with Hormone Ablation Therapy for Prostate Cancer (Seminar). International Academy of Pathology, Arab Division, WHO Sponsored 7th Scientific Meeting. University of Damascus, Faculty of Medicine, Syria
- 1998 The role of Grade, Proliferation Index and p53 status in Predicting Outcome in Hepatoma Following Transplantation, Damascus University, Faculty of Medicine, Damascus, Syria
- 1998 Tumors of the Male Genital and Urinary Systems: A Review Course. Damascus University, Faculty of Medicine, Damascus, Syria
- 1998 The Use of Orthotopic Liver Transplantation in Hepatocellular Carcinoma: The Role of Prognostic Parameters. Department of Pathology, American University of Beirut, Lebanon
- 2001 Diagnostic Molecular Pathology for the Anatomic Pathologist. American University of Beirut, Lebanon
- 09/2001 Diagnostic Molecular Pathology: Current & Future Impact on Anatomic Pathology. Two parts seminar. International Academy of Pathology, Arab Division (IAP-AD) 13th Annual Meeting, Damascus University, Damascus, Syria
- 03/2007 Secondary Tumors of the Genitourinary Tract, International Society of Urologic Pathology (ISUP), USCAP Companion Meeting, San Diego, CA
- 11/2007 Prognostic Factors in Urothelial Carcinoma of Bladder, The XXVI Congress of the Brazilian Society of Pathology, Long Course, Rio Grande De Sul, Brazil
- 11/2007 Urothelial Carcinoma of Bladder: Molecular Pathways, The XXVI Congress of the Brazilian Society of Pathology, Long Course, Rio Grande De Sul, Brazil
- 11/2007 Molecular Aspects of Prostate Carcinoma, The XXVI Congress of the Brazilian Society of Pathology, Long Course, Rio Grande De Sul, Brazil
- 11/2007 Prognostic Factors in Renal Cell Carcinoma, The XXVI Congress of the Brazilian Society of Pathology, Long Course, Rio Grande De Sul, Brazil
- 11/2007 Renal Cell Carcinoma: Update on Molecular Aspects, The XXVI Congress of the Brazilian Society of Pathology, Long Course, Rio Grande De Sul, Brazil
- 12/2007 Testicular Germ Cell Neoplasia: Molecular Pathways and Challenging Morphologic Aspects, The 19th Annual Meeting of the International Academy of Pathology, Arab Division (IAP-AD), University of Aleppo, Faculty of Medicine, Aleppo, Syria
- 12/2007 Urothelial Carcinoma of Bladder: Molecular Pathways & Prognostication, The 19th Annual Meeting of the International Academy of Pathology, Arab Division (IAP-AD), University of Aleppo, Faculty of Medicine, Aleppo, Syria
- 12/2007 Renal Cell Carcinoma: Familial Inheritance & Molecular Aspects, Grand Round Lecture, Department of Pathology, Damascus University, Faculty of Medicine, Damascus, Syria
- 07/2008 Urothelial Carcinoma of Urinary Bladder, Clinicopathologic Prognosticators, Molecular Pathways and Targets of Therapy, Clemenceau Medical Centre, Johns Hopkins International, Beirut, Lebanon
- 01/2009 Molecular Testing of Solid Tumors in the Era of Targeted Therapy: Crucial Diagnostic, Prognostic & Therapy Prediction Tools, American University of Beirut Faculty of Medicine, Department of Pathology and Laboratory medicine and Nayef Basile Cancer Center Cancer Centre, Beirut, Lebanon
- 08/2009 An update on the Molecular Aspects of Prostate Cancer, The 6th Asia Pacific International Academy of Pathology (IAP) Congress, Kochin, India

- 08/2009 Urothelial carcinoma of the Bladder. A morphologic Guide to WHO/ISUP Grading, Challenging Histology Variants and Current Prognostic Parameters. The 6th Asia Pacific International Academy of Pathology (IAP) Congress, Kochin, India
- 09/2009 Meet The Expert: Urothology. The 22nd European Congress of Pathology. Florence, Italy
- 11/2009 Meet The Expert: Urothology. The 8th Middle East Oncology Congress, Beirut, Lebanon
- 11/2009 Molecular Diagnostics of Solid Tumors: A crucial Tool in the Era of Targeted Personalized Oncologic Therapy (part I). The 8th Middle East Oncology Congress, Beirut, Lebanon
- 11/2009 Molecular Diagnostics of Solid Tumors: A crucial Tool in the Era of Targeted Personalized Oncologic Therapy (part II). The 8th Middle East Oncology Congress, Beirut, Lebanon
- 11/2009 Urothelial Carcinoma of Bladder: A Histologic and Cytopathologic Guide to WHO-ISUP Grading Scheme and Challenging Variants - The 8th Middle East Oncology Congress Beirut, Lebanon
- 11/2009 An Update on Molecular Aspects of Prostate Cancer. The 8th Middle East Oncology Congress, Beirut, Lebanon
- 02/2010 The Molecular Diagnostic - Anatomic Pathology Interface: Crucial Diagnostic, Prognostic and Theranostic Applications Clemenceau Medical Centre, Johns Hopkins International, Beirut, Lebanon
- 05/2010 Achieving a Triumph over Cancer in Chile & Latin America: *Clínica Las Condes Centro Clínico de Cancer*. Cancer Centre Launch Ceremony, Clinica Las Condes; Johns Hopkins International, Santiago, Chile
- 10/2010 Molecular Biology of Human Prostate Cancer. XXVIIIth International Congress of the International Academy of Pathology, Sao Paulo, Brazil
- 10/2010 Pseudocarcinomatous Hyperplasia of Urinary Bladder. XXVIIIth International Congress of the International Academy of Pathology, Sao Paulo, Brazil
- 12/2010 Molecular Diagnostic of Solid Tumors: Crucial Diagnostic, Prognostic and Theranostic Applications. The XXII International Academy of Pathology Arabic Division (IAP AD) Annual Meeting, Cairo, Egypt
- 02/2011 The Molecular Pathology of Bladder Carcinoma and Future Perspectives. International Society of Urologic Pathology (ISUP) USCAP Companion Meeting, San Antonio, TX
- 04/2011 Molecular Markers of Prognostication in Urothelial Carcinoma of the Urinary Bladder: A Status Update. University of Ancona, Ancona, Italy
- 04/2011 "Aiming to Achieve a Triumph over Cancer in Chile & Latin America: *Clínica Las Condes Centro Clínico de Cancer*. Clinica Las Condes & Johns Hopkins International". University of Verona, Verona, Italy
- 04/2011 Molecular Pathways in Prostate Carcinoma: A Status Update (A visiting professor lecture, Medical Students Pathology Curriculum), University of Verona, Verona, Italy
- 04/2011 Molecular Markers of Prognostication in Urothelial Carcinoma of the Urinary Bladder: A Status Update. University of Verona, Verona, Italy
- 05/2011 The Role of the Anatomic Pathologist in the Era of Targeted Therapy of Solid Tumors. Gazi University, Ankara, Turkey
- 05/2011 Neoplasms of the Urinary Bladder: A Workshop. Hacettepe University, Ankara, Turkey
- 05/2011 Testicular Trophoblastic Tumors. Testicular Neoplasms: Surgical Pathology Course, Ankara University, Ankara, Turkey
- 05/2011 Germ Cell Tumor Metastases and Somatic Malignancies developing in the germ cell tumors. Testicular Neoplasms: Surgical Pathology Course, Ankara University, Ankara, Turkey
- 05/2011 Pathogenesis of Germ Cell Tumors. Testicular Neoplasms: Surgical Pathology Course
- 05/2011 Sex Cord/Gonadal Stromal Tumors. Testicular Neoplasms: Surgical Pathology Course, Ankara University, Ankara, Turkey
- 05/2011 Rete and Collecting Ducts Tumors. Testicular Neoplasms: Surgical Pathology Course, Ankara University, Ankara, Turkey

- 08/2011 European Society of Pathology Congress 2011; Uropathology Case Discussion Seminar Presenter and Co-Chair, Helsinki, Finland
- 09/2011 Académie Internationale de Pathologie Division Française 11e Journée de Formation Médicale Continue avec Invités Etrangers (The 11th CME Course of The International Academy of Pathology: French Division); Morceaux choisis en uropathologie (Selected Topics in Uropathology), University of Paris, Cochin Hospital, Paris, France
- 03/2012 United States and Canadian Academy of Pathology 2012 Annual Meeting; Special Course: A Practical Guide to Molecular Testing In Cancer Clinical Applications of Recent Molecular Advances in Urologic Malignancies: No Longer Chasing a "Mirage". Vancouver, Canada
- 08/2012 The Molecular Pathology of Bladder Carcinoma and Future Perspectives. Department of Anatomic Pathology; A.C. Camargo Cancer Centre (Hospital A.C. Camargo); São Paulo – Brazil
- 08/2012 Urothelial carcinoma of the bladder: a morphologic guide to challenging histologic variants, mimickers and current prognostic parameters. Department of Anatomic Pathology A.C. Camargo Cancer Centre (Hospital A.C. Camargo), São Paulo – Brazil
- 09/2012 International Academy of Pathology (IAP): The Biannual International Congress. "Molecular Changes in Bladder Cancer", Cape Town South Africa
- 09/2012 International Academy of Pathology (IAP): Indian Division 15th CME 2012, Department Of Pathology, Armed Forces Medical College. "Novel Prognostic & Detection Approaches in Prostate Cancer", Pune, India
- 09/2012 International Academy of Pathology (IAP): Indian Division 15th CME 2012, Department Of Pathology, Armed Forces Medical College. "Challenging Genitourinary Cancers". Pune, India
- 02/2013 United States & Canadian Academy Of Pathology (USCAP) 2013 Annual Meeting. *Special Course: A Practical Guide to Molecular Testing In Cancer*. Clinical Applications of Recent Molecular Advances in Urologic Malignancies: No Longer Chasing a "Mirage" Baltimore, MD
- 05/2013 3rd EACR-OECI Joint Training Course "Molecular Pathology Approach To Cancer". The Molecular Pathology of Prostate Cancer, Amsterdam, Netherland
- 07/2013 I Congresso de Oncologia D'Or: Meeting with Johns Hopkins Experts. Molecular Diagnostic Pathology for Solid Tumor Oncology in the Era of Personalized Medicine - State of the art. Rio De Janeiro, Brasil
- 07/2013 I Congresso de Oncologia D'Or: Meeting with Johns Hopkins Experts. Molecular Advances in Prostate Cancer Screening: Beyond PSA. Rio De Janeiro, Brazil
- 07/2013 I Congresso de Oncologia D'Or: Meeting with Johns Hopkins Experts. Emerging Prognostic Biomarkers in Urothelial Carcinoma. Rio De Janeiro, Brazil
- 11/2013 The 23rd Congress of The Turkish Society of Pathology. Histological Variants Bladder Cancer, Clinical Importance and Secondary Malignancies. Izmir, Turkey
- 11/2013 The 23rd Congress of The Turkish Society of Pathology. WHO - ISUP Classification in Urothelial Carcinoma Izmir, Turkey
- 11/2013 The 23rd Congress of the Turkish Society of Pathology. Histological Changes and Reporting of Prostate Cancer following Non-surgical Treatment Izmir, Turkey
- 11/2013 The 23rd Congress of the Turkish Society of Pathology. Oncologic Surgical Pathology in the Era of Precision Medicine Izmir, Turkey
- 11/2013 The 29th Congress of the Brazilian Society of Pathology. Molecular Pathology in Bladder Cancer, Florianopolis, Brazil
- 01/2014 The 3rd St. Luke's International Pathology Symposium the Molecular Pathology of Genitourologic Malignancies St Luke's School of Medicine, Manila, Philippines
- 01/2014 The 3rd St. Luke's International Pathology Symposium Adult Renal Tumors: ISUP 2012 Vancouver Update St Luke's School of Medicine, Manila, Philippines
- 01/2014 The 3rd St. Luke's International Pathology Symposium

- WHO - ISUP Classification in Urothelial Carcinoma: Refining Grading and Staging St Luke's School of Medicine, Manila, Philippines
- 03/2014 United States and Canadian Academy of Pathology 2014 Annual Meeting; Short Course: Pathology in the era of genomic medicine: New frontiers and new challenges San Diego, CA
- 05/2014 4th EACR-OECI Joint Training Course "Molecular Pathology Approach to Cancer" The Molecular Pathology of Bladder Cancer. Amsterdam, Netherland
- 05/2014 The European Society of Pathology- Urothology Working Group & The Turkish Society of Pathology Joint Meeting Urinary bladder: Flat lesions Ankara, Turkey
- 05/2014 The European Society of Pathology- Urothology Working Group & The Turkish Society of Pathology Joint Meeting Mesenchymal Tumors of the Prostate Ankara, Turkey
- 05/2014 The European Society of Pathology- Urothology Working Group & the Turkish Society of Pathology Joint Meeting Contemporary Role of Ancillary Techniques in Renal Cell Neoplasia Diagnosis and Prognosis Ankara, Turkey
- 05/2014 The European Society of Pathology- Urothology Working Group & The Turkish Society of Pathology Joint Meeting Pathogenesis of Germ Cell Tumors Ankara, Turkey
- 05/2014 The European Society of Pathology- Urothology Working Group & The Turkish Society of Pathology Joint Meeting
- 05/2014 The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Ankara, Turkey
- 05/2014 The European Society of Pathology- Urothology Working Group & The Turkish Society of Pathology Joint Meeting Urothelial Carcinoma of Bladder: A Morphologic Guide to Challenging Histologic Variants Ankara, Turkey
- 05/2014 4th EACR-OECI Joint Training Course "Molecular Pathology Approach to Cancer" The Molecular Pathology of Bladder Cancer, Amsterdam, Netherland
- 05/2014 The European Society of Pathology- Urothology Working Group & The Turkish Society of Pathology Joint Meeting Tumours of the Urinary System and Male Genital Organs Ankara, Turkey
- 09/2014 "Presidential Lecture" in Urothology: Genomic Applications in Pathology: Personalized Medicine in Oncologic Pathology 26th European Congress of Pathology - London, England
- 10/2014 Old, New and Emerging Entities in Renal Cell Neoplasia: ISUP 2012 Vancouver Classification Update XXXII Saltykow Memorial Meeting - University of Zagreb, Zagreb, Croatia Gleason Grade: 2005 ISUP Consensus Conference Update and Beyond
- 10/2014 XXXII SALTYKOW MEMORIAL MEETING University of Zagreb, Zagreb, Croatia
- 10/2014 Bladder Cancer: Slide Seminar Workshop XXXII Saltykow Memorial Meeting University of Zagreb, Zagreb, Croatia
- 10/2014 Molecular Advances in Bladder Cancer XXXII Saltykow Memorial Meeting University of Zagreb, Zagreb, Croatia
- 10/2014 Molecular pathology and bladder cancer: Evolving concepts 30th International Congress of the International Academy of Pathology (IAP2014) Bangkok, Thailand
- 11/2014 Molecular Anatomic Pathology in the Era of Precision Medicine: Maintaining our Turf 45th Congress of the Argentine Society of Pathology 2014, Buenos Aires, Argentina
- 11/2014 Urothelial Carcinoma: Slide Seminar Workshop 45th Congress of the Argentine Society of Pathology 2014 Buenos Aires, Argentina
- 11/2014 Update in Renal Cell Carcinoma: The Vancouver ISUP Consensus 45th Congress of the Argentine Society of Pathology 2014, Buenos Aires, Argentina
- 03/2015 MiTF Translocation Renal Cell Carcinoma The XVIII Pathology Meeting of the EPOAHT Urothology Course A.C.CAMARGO CANCER CENTER, Sao Paulo, Brazil
- 03/2015 Molecular Aspects of Prostate Cancer, The XVIII Pathology Meeting of the EPOAHT Urothology Course A.C.CAMARGO CANCER CENTER, Sao Paulo, Brazil
- 03/2015 Flat Urothelial Lesions of the Urinary Tract The XVIII Pathology Meeting of the EPOAHT Urothology Course A.C.CAMARGO CANCER CENTER Sao Paulo, Brazil

- 03/2015 Molecular Aspects of Bladder Carcinoma The XVIII Pathology Meeting of the EPOAHT Uropathology Course A.C.CAMARGO CANCER CENTER, Sao Paulo, Brazil
- 09/2015 27th European Congress of Pathology (ECP/ESP). Molecular Taxonomy of Bladder Cancer: Where Are We? Belgrade, Serbia
- 10/2015 Department Of Urology, University of San Paulo. "New concepts of prognostic aspects of prostate cancer on biopsies and radical prostatectomy specimens" Sao, Paulo, Brazil
- 11/2015 30th Brazilian Congress of Pathology – Renal Cell Cancer "Evolving Paradigms in Renal Cell Carcinoma: The ISUP Vancouver Update" Slide Seminar and Mini Symposium "Uropathology", Sao Paulo, Brazil
- 04/2016 The Serbian Society of Pathology Symposium: Oncogenesis Myths and Facts. A Novel Molecular Taxonomy of Bladder Cancer: Light at the End of the Tunnel. Zlatibor, Serbia
- 10/2016 2nd Annual Meeting of the Japan Society of Urologic Oncology (JSUO). Toward Personalized Management in Bladder Cancer: The Promise of Novel Molecular Taxonomy. Yokohama, Japan
- 03/2017 EAU17 "32nd Anniversary Congress of the European Association of Urology" Joint meeting of the EAU Section of Urological Pathology (ESUP) and the EAU Section of Urological Research (ESUR) Moderator, London, United Kingdom
- 05/2017 European Society of Pathology, Genitourinary Working Group: An Update in the Era of Personalized Therapy. Non-germ cell tumors of the testis and tumors of paratesticular structures. Florence, Italy
- 05/2017 European Society of Pathology, Genitourinary Working Group: An Update in the Era of Personalized Therapy. Immune checkpoint pathway in bladder carcinoma. Florence, Italy
- 05/2017 European Society of Pathology, Genitourinary Working Group: An Update in the Era of Personalized Therapy. Molecular advances bladder cancer: novel genomic based prognostics and predictors. Florence, Italy
- 05/2017 European Society of Pathology, Genitourinary Working Group: An Update in the Era of Personalized Therapy. Molecular pathology of germ cell tumors: approach for tailored therapy. Florence, Italy
- 06/2017 26th Ljudevit Jurak International Symposium on Compative Pathology: "Personalized management in bladder cander: The promise of novel molecular taxonomy. Zagreb, Croatia
- 06/2017 26th Ljudevit Jurak International Symposium on Compative Pathology: "A bullish outlook on the future of anatomic pathology in the era of precision medicine. Zagreb, Croatia
- 09/2017 29th European Congress of Pathology (ECP/ASP): "Molecular pathology of prostate cancer. Amsterdam, Holland
- 10/2017 European Association of Urology Section of Urological Research (ESUR). Immune scoring system in modern pathology: A new grading system? Paris, France
- 11/2017 The 9th European Multidisciplinary Symposium on Genitourinary Pathology and Molecular diagnostics (EMUC): PDL1 testing and immunotherapy for genitourinary organs. Barcelona, Spain
- 11/2017 Brasilian Society of Pathology Bi-Annual Meeting 2017. Application of immunohistochemical biomarkers in diagnosis and prognosis in urological tumors. Belo Hrizonti, Brazil
- 11/2017 Assembly of Asia Pacific International Academy of Pathology (AAPIAP) & Hong Kong Division of IAP: Surgical Pathlogy Update and Junior Academy: Genomic advances in prostate cancer; Saigon, Vietnam
- 11/2017 Assembly of Asia Pacific International Academy of Pathology (AAPIAP) & Hong Kong Division of IAP: Personalized management in bladder cancer: the promise of novel molecular taxonomy; Saigon, Vietnam
- 11/2017 Assembly of Asia Pacific International Academy of Pathology (AAPIAP) & Hong Kong Division of IAP: A bullish outlook on the future of anatomic pathology in the era of precision medicine. Saigon, Vietnam
- 12/2017 Precision Oncologic Pathology: The Convergence of Genomics & Immunotherapy.

University of Zagreb, Zagreb, Croatia
01/2018 6th Techno-Urology Meeting: Molecular approach to prostate cancer grading. Turin, Italy.

INVITED TALKS AND SEMINARS – NATIONAL

- 1996 Urologic Pathology Course. Anatomic Pathology Board Review Osler Institute of Pathology, San Diego, CA
- 1997 Urologic Pathology Course. Anatomic Pathology Board Review Osler Institute of Pathology Dallas, TX
- 05/2002 Logical Approach to the Unknown Primary Cancer. Educational Session American Society of Clinical Oncology (ASCO) 38th annual meeting, Orlando, FL
- 04/2006 Image Analysis: A high throughput solution for biomarker expression & genetic alteration analysis using tissue microarrays. The G.O.T Summit, Cambridge Healthtech Institute, Boston, MA
- 09/2008 Urothelial Carcinoma Of Bladder A Morphologic Guide To WHO/ISUP Grading Scheme, Challenging Histologic Variants And Mimickers A Video Course. College of American Pathology Annual Meeting 2008, San Diego, CA
- 09/2008 Urothelial Carcinoma of Bladder A Morphologic Guide To WHO/ISUP Grading Scheme, Challenging Histologic Variants, Mimickers And Current Prognostic Parameters, College of American Pathology Annual Meeting 2008, San Diego, CA
- 11/2008 Molecular Testing of Solid Tumors in the Era of Targeted Therapy: Crucial Diagnostic & Therapy Prediction Tools, National Arab American Association (NAAMA) Annual Meeting 2008, Washington, D.C.
- 10/2009 Urothelial Carcinoma of Bladder A Morphologic Guide To WHO/ISUP Grading Scheme, Challenging Histologic Variants And Mimickers A Video Course. College of American Pathology Annual Meeting 2009, Washington, D.C.
- 2009 Urothelial Carcinoma of Bladder A Morphologic Guide To WHO/ISUP Grading Scheme, Challenging Histologic Variants, Mimickers And Current Prognostic Parameters, College of American Pathology Annual Meeting 2009, Washington, D.C.
- 10/2009 The Immunohistochemistry- Molecular Interface: Diagnostic, Therapeutic and Genomic Applications in Urologic Malignancies. American Society of Clinical Pathology Annual Meeting, 2009, Chicago, IL
- 10/2009 Urothelial Carcinoma of Bladder A Morphologic Guide To WHO/ISUP Grading Scheme, Challenging Histologic Variants And Mimickers A Video Course. College of American Pathology Annual Meeting 2010, Chicago, IL
- 10/2010 Urothelial Carcinoma of Bladder A Morphologic Guide To WHO/ISUP Grading Scheme, Challenging Histologic Variants, Mimickers And Current Prognostic Parameters, College of American Pathology Annual Meeting 2010, Chicago, IL
- 10/2010 Molecular Advances in Urologic Malignancies: Diagnostics, Therapeutics and Genomic Applications. College of American Pathology Annual Meeting 2010, Chicago, IL
- 11/2010 Urothelial Carcinoma: The World Health Organization/International Society of Urologic Pathology Grading Scheme, Challenging Histologic Variants and Mimickers. American Society of Clinical Pathology Telepathology Seminars series
- 8/2011 Cambridge Healthtech Institute (CHI) Third Annual Next Generation Dx Summit: Emerging Molecular Markers of Cancer, "Emerging Molecular and Immunohistochemical Markers of Detection and Prognostication in Prostate Cancer" - Washington, D.C.
- 10/2011 Urothelial Carcinoma of Bladder, A morphologic guide to WHO/ISUP grading Scheme, Clinicopathologic Prognostic Parameters. American Society of Clinical Pathology Teleconferences and Livewebcasts Seminars series

- 10/2011 Urothelial Carcinoma Update: Pathogenesis, Challenging Histologic Variants and Diagnostic Mimickers. American Society of Clinical Pathology Teleconferences and Livewebcasts Seminars series
- 06/2012 Cambridge Healthtech Institute (CHI): Innovative Tissue-Based Diagnostics: Pathology in Cancer Drug Development session. "mTOR Pathway in Urologic Malignancies: A therapeutic Target and A Potential Progonsticator" - Philadelphia, USA
- 09/2012 Molecular Advances in Urologic Malignancies: Diagnostics, Theranostics and Genomic Applications. College of American Pathology Annual Meeting 2012, San Diego, CA
- 04/2014 Prostate Advanced Practical Pathology Program (AP3) The College of American Pathology (CAP) "The Gleason Grading", Chicago, IL
- 04/2014 Prostate Advanced Practical Pathology Program (AP3) The College of American Pathology (CAP) "Biomarkers", Chicago, IL
- 11/2014 Prostate Advanced Practical Pathology Program (AP3) The College of American Pathology (CAP) "The Gleason Grading", Chicago, IL
- 11/2014 Prostate Advanced Practical Pathology Program (AP3) The College of American Pathology (CAP) "Prostate Cancer Biomarkers", Chicago, IL
- 05/2017 Association of Clinical Scientists 2017 Annual Meeting. "A Bullish Outlook on the Future of Anatomic Pathology in the Era of Precision Medicine", Birmingham, AL
- 08/2017 Next Generation Summit, The Big Picture of Diagnostics: Genomic Advances in Urinary Bladder Cancer: Taxonomy, Therapeutic Targets and More. Washington, DC

INVITED TALKS AND SEMINARS – REGIONAL

- 1994 Prostatic Intraepithelial Neoplasia (PIN), Prostate Update Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY
- 1994 Programmed Cell Death: Apoptosis, Department of Pathology, State University of New York, Stony Brook, NY
- 1997 Hepatocellular Carcinoma: An Update, Sammons Cancer Center, Baylor University Medical Center, Dallas, TX
- 1999 HER-2/neu (C-erb B-2) Oncogene: Prognostic Factor and Target of Therapy, Sammons Cancer Center, Baylor University Med Center, Dallas, TX
- 2000 Liver Allograft Rejection: Pathobiology and Morphology, Baylor Institute for Transplantation, Dallas, TX
- 2003 Diagnostic Molecular Pathology: Applications to Oncology, Case Management, Internal Medicine Grand Round, Baylor University Medical Center, Dallas, TX
- 2004 Molecular Diagnostics: Applications to Anatomic Pathology, Washington Hospital Center, Washington, D.C.
- 2004 The Assimilation of Molecular Diagnostics by Anatomic Pathologists, Veterans Affairs Medical Center, Washington, D.C.
- 2005 Molecular Diagnostic Pathology, Applications to Gastrointestinal Diseases, Gastroenterology Fellowship Lecture Series, Georgetown University and VAMC, Washington, D.C.
- 2005 Molecular Diagnostics: Applications to Anatomic Pathology: Two part seminar, The George Washington University Hospital, Washington, D.C.
- 2006 Selected Topics in Testicular Germ Cell Neoplastic Diseases, Maryland Society of Pathologists, Ellicott City, MD
- 2006 Renal Cell Tumors: Molecular and Morphologic Update, the George Washington University Hospital, Washington, D.C.
- 2006 Testicular Germ Cell Neoplasm: An Update, the George Washington University Hospital, Washington, D.C.
- 2007 Secondary Tumors of Genitourinary System: Identifying the Primary Site of Origin. Brady Urologic Oncology Grand Rounds, Johns Hopkins University, Baltimore, MD
- 02/2008 Diagnostic Mimickers of Prostate Adenocarcinoma and Prostatic Intraepithelial Neoplasia (PIN), Department of Pathology, National Institutes of Health (NIH/NCI), Bethesda, MD

- 05/2008 Renal Cell Carcinoma: Molecular Pathways and Prognostic Indicators, Department of Pathology, University of Medicine and Dentistry of New Jersey (UMDNJ), Newark, NJ
- 05/2008 Urothelial Carcinoma of Urinary Bladder: Morphologic Guide to the WHO/ISUP Classification, Challenging Variants and Benign Mimickers, Department of Pathology Grand Rounds, University of Medicine and Dentistry of New Jersey (UMDNJ), Newark, NJ
- 05/2008 Renal Neoplasms: A Morphologic and Prognostic Parameters Update, University of Louisville, "The Anatomic & Clinical Pathology Update," Louisville, KY
- 05/2008 Mimickers of Prostate Adenocarcinoma & High Grade Prostatic Intraepithelial Neoplasia (HGPIN), University of Louisville "The Anatomic & Clinical Pathology Update," Louisville, KY
- 10/2008 Urothelial Carcinoma of Urinary Bladder Clinicopathologic Prognosticators, Molecular Pathways and Targets of Therapy, Pathology Grand Rounds, Johns Hopkins University, Baltimore, MD
- 11/2008 Urothelial Carcinoma Of Urinary Bladder Clinicopathologic Prognosticators, Molecular Pathways and Targets of Therapy The Alexander Breslow Lectureship in Pathology, Department of Pathology, George Washington University, Washington, D.C.
- 01/2009 Urothelial Carcinoma of the Urinary Bladder: Prognosticators, Molecular Pathways and Targets of Therapy Update, Department of Pathology Grand Rounds, Georgetown University School of Medicine, Washington, D.C.
- 01/2009 Urothelial Carcinoma of the Bladder: A Morphologic Guide to WHO/ISUP Grading Scheme, Challenging Histologic Variants and Mimickers, Department of Pathology, National Institutes of Health (NIH/NCI), Bethesda, MD
- 01/2010 The Molecular Diagnostic - Anatomic Pathology Interface: Crucial Diagnostic, Prognostic and Theranostic Applications, Division of Molecular Pathology, Johns Hopkins University, Baltimore, MD
- 04/2010 Prostate Cancer and Atypical Glands Foci: A Morphologic Guide to Evaluation of Prostate Needle Biopsy, Montana State Society of Pathology, 2010 Annual Meeting, Helena, MT
- 04/2010 A Practical Approach to Identifying Mimickers of Prostate Adenocarcinoma & High Grade Prostatic Intraepithelial Neoplasia (HGPIN), Montana State Society of Pathology, 2010 Annual Meeting, Helena, MT
- 04/2010 Mesenchymal Tumors of the Prostate, Montana State Society of Pathology, 2010 Annual Meeting, Helena, MT
- 08/2010 Molecular Diagnostics in Solid Tumors Oncology: Making the Promise of Personalized Management Attainable, Pathology Grand Round Lecture, Memorial Sloan Kettering Cancer Centre, New York
- 11/2010 Molecular Diagnostics in Solid Tumor Oncology, Maryland Society of Pathologists, Baltimore
- 02/2011 The Molecular Diagnostics – Anatomic Pathology Interface: Crucial Diagnostic, Prognostic and Theranostic applications, Pathology Grand Round Lecture, Johns Hopkins University
- 07/2011 Advanced Course on Prostate Cancer Management, *Clinical Pathology Aspects of Prostate Cancer*, Johns Hopkins University
- 01/2013 Molecular Pathology Update in Penile Carcinoma Grand Rounds at Brady Urological Institute Department of Urology Johns Hopkins University
- 03/2017 Georgetown University Seminar Series. Kidney and Bladder Cancers: Updates on Clinical Management 2017 Conference, Washington, D.C.

SERVICE RESPONSIBILITIES

- 1994 – Present Urologic Pathology (25%)
- 2000 – Present Molecular Diagnostic Pathology (10%)

CLINICAL PROGRAM BUILDING/LEADERSHIP

- 2000-2004 Director of Molecular Diagnostic Pathology Laboratory, Baylor University Medical Centre
- Led program building activities of establishing and directing a state of the art Molecular Diagnostic Laboratory to serve the Baylor Health Care System Network & US Oncology Cancer Centre in Dallas Texas.
- 2009 – 2011 Chair of Anatomic Pathology Molecular Diagnostic Steering Committee, Johns Hopkins University
- Led gap analysis of the status of molecular diagnostic testing for solid tumors and assessed clinical needs in stakeholder departments and divisions and Sidney Kimmel Comprehensive Cancer Centre
- Outcome: Expanded menu of molecular diagnostic test resulted in multiple folds increment in solid tumor ordered molecular tests and a shortened turn around time for originally sent out tests.
- 2011-2016 Director of Surgical Pathology Molecular Diagnostics, Johns Hopkins University
- Guided in-house implementation of new molecular tests needed for solid tumor diagnostics, prognostics and predictors of response to novel targeted therapy
 - Supervised refinements of electronic ordering and molecular results report integration into routine anatomic pathology
- 2016- Present Chair, Department of Pathology, UAB Medicine

SYSTEM INNOVATION AND QUALITY IMPROVEMENT PROGRAM BUILDING/LEADERSHIP

- 2010 – 2015 Johns Hopkins International (JHI) Medical Director of Clinica Las Condes Cancer Centre, JHI affiliate Hospital in Santiago, Chile

Role: Led a Johns Hopkins International team tasked with drawing a strategic plan based on a Strength, Weaknesses, Opportunities and Threats (SWOT) analysis, designing a cancer centre organizational structure and identifying key medical and administrative cancer centre players. Activities included: on site visits to Santiago; weekly video teleconferences; bringing several clinical and administrative teams from Clinca Las Condes to Johns Hopkins University in close collaboration with Sidney Kimmel Comprehensive Cancer Centre director and staff; assist in recruiting new onsite cancer centre director and radiation oncology department director at Clinical Las Condes

Outcome: Succeeded in achieving a buy-in from vested clinical services (oncology, radiation oncology, surgical opting multidisciplinary quality driven oncology care plan based on National Cancer Centers Network (NCCN) protocols. Continued to initiate academic and research opportunities for collaboration with Johns Hopkins University, establish outcome and quality measures and work with Clinca Las Condes hospital administration on marketing and third party payer strategies